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Summary 
Summary 
 
This dissertation presents fragment screening studies against two human proteins Siah1 
and SENP1, which function in post-translational modification pathways. Siah1 is an E3 
ubiquitin ligase that functions as a scaffold to transfer ubiquitin bound to an E2 
ubiquitin-conjugating enzyme to a substrate as part of the ubiquitination pathway. 
SENP1 is a cysteine protease that catalyses two essential reactions in the SUMO 
pathway. It processes pre-SUMO proteins to their mature form and removes SUMO 
from the target proteins. Siah1 interactions with other proteins involve large surface 
areas, while SENP1 has a small active site, making it hard to identify ligands for these 
proteins. The fragment-based approach has emerged as a complementary method to 
high-throughput screening of finding novel small molecules. The main aim of the study 
was to examine whether fragment screening would identify any ligands against these 
targets. 
Chapter 1 introduces post-translational modifications and presents fragment-based 
approach used in drug discovery. Chapter 2 describes the experimental methods used. 
The results from fragment screening against Siah1 using SPR and DSF are reported in 
chapter 3. The chapter also presents the structure of Siah1 refined to 1.95 Å that 
displays new parts of the structure, previously missing due to the absence of reliable 
electron density. Chapter 4 contains results from the fragment screens against SENP1 
using DSF and NMR. The crystal structure of SENP1 was determined with a number of 
improvements made over earlier structures.      
Besides performing fragment screening, the binding between Siah1 interacting proteins 
reported in the literature and Siah1 was investigated. A number of Siah1 binding 
partners were successfully expressed and purified as described in chapter 5. One of 
XII 
 
 
Summary 
those, SIP showed a clear interaction with Siah1, as observed by the shift on a size 
exclusion column of the complex relative to the individual protein species. Siah1 was 
reported to collaborate with PEG3 in the regulation of β-catenin degradation. A SCAN 
domain, located at the N-terminus of PEG3, was tested for binding using gel filtration 
chromatography and NMR, but no interaction was observed. PEG3 was used in the 
crystallographic studies and a structure of its SCAN domain was solved using molecular 
replacement and refined to 1.95 Å. The structure of PEG3-SCAN domain revealed a 
stable homodimer with an extensive dimerization interface.  
The structure of a zinc-dependent cytosolic carboxypeptidase from Burkholderia 
cenocepacia was determined and is reported in chapter 6. This work was a side project 
assessing a new refinement strategy, which involved the use of the automated protocols 
embedded in the PDB_REDO server. The structure revealed that carboxypeptidase is a 
tetramer and provides details of its active site, whose spatial conformation of residues 
supports the notion that the protein might function as a deglutamylase. 
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Chapter 1- Introduction: Targeting post-translational modifications using fragment-based approach 
1.1 Preface 
Most proteins undergo some form of chemical alteration following translation. These 
post-translational modifications confer different properties to the proteins, thereby 
generating protein heterogeneity. Two such modifications are ubiquitination and 
SUMOylation, which regulate nearly every aspect of eukaryotic cell biology, including 
gene transcription, cellular localisation and protein stability. These modifications are 
carried out by a set of different proteins. Two specific proteins called Siah1 and SENP1; 
belonging to an E3 ubiquitin ligase and cysteine protease families are introduced in the 
following chapter. Accumulating evidence suggests that their misregulation is 
associated with the development of various cancers. Specific potent inhibitors of Siah1 
and SENP1 are therefore required to validate these as therapeutic targets. 
Identification of enzyme inhibitors and protein ligands to modulate biological function 
is the foundation of drug discovery. One approach to identify the first ligands is to 
screen large libraries of compounds with molecular weights of around 500 Da, known 
as high-throughput screening (HTS). However, practice showed that hits identified are 
difficult to optimise further. An alternative approach involves the screening of 
compounds of low complexity, known as fragment-based method. This differs from 
HTS in terms of library size and screening methods, and hits identified provide better 
starting points for subsequent drug development. Fragment-based methodology has 
been successful against some targets like kinases and is now expanding to other protein 
classes. Herein the fragment screening process is described and the question is asked 
whether this method can generate ligands targeting protein-protein interactions and 
poorly accessible active sites such as present in Siah1 and SENP1 proteins.  
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Chapter 1- Introduction: Targeting post-translational modifications using fragment-based approach 
1.2 Post-translational modifications 
Post-translational modification (PTM) is the covalent attachment of a chemical group or 
a peptide to the protein following translation (Walsh et al., 2005). PTMs increase the 
functional diversity of the proteome and provide an additional level of protein control, 
which is often reversible. The common modifications include phosphorylation (Ubersax 
and Ferrell, 2007), glycosylation (Spiro, 2002), S-nitrosylation (Gaston et al., 2003), 
methylation (Grewal and Rice, 2004) and N-acetylation (Glozak et al., 2005). PTMs 
regulate a variety of processes such as gene transcription (Waby et al., 2008) and 
protein degradation (Orford et al., 1997); thereby their understanding is critical in the 
study of cell biology.   
1.2.1 Ubiquitination 
Ubiquitination is another type of PTM with a role in numerous biological processes 
(Grabbe et al., 2011). One of the best studied is its function in targeting proteins for 
destruction by the 26S proteasome, a large multisubunit protease. It is known as the 
ubiquitin-proteasome system (UPS) and is the main proteolytic pathway of eukaryotic 
cells. It helps the cell to maintain protein homeostasis, a balance between the newly 
synthesised proteins and degradation of damaged or no longer required proteins, 
accumulation of which may otherwise be harmful (Hoeller and Dikic, 2009). Not 
surprisingly, misregulation of protein degradation is associated with many diseases that 
range from cancer to autoimmune and neurodegenerative disorders (Hershko and 
Ciechanover, 1998; Martens and Stunnenberg, 2010). Therefore, the UPS is an 
attractive target for therapeutic intervention and drugs such as bortezomib that inhibits 
the proteasomal machinery are already used to treat malignancies such as multiple 
myeloma and mantle cell lymphoma (Shah and Orlowski, 2009; Mohty et al., 2012).   
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In UPS, the proteins are targeted for degradation by the addition of highly conserved 
ubiquitin molecules (76 amino acids, ~8.5 kDa). Ubiquitination is a multistep process 
requiring the activity of three classes of enzymes: an ATP-dependent ubiquitin-
activating (E1), ubiquitin-conjugating (E2) and ubiquitin ligase (E3) proteins (Figure 
1.1; Hershko and Ciechanover, 1998). In the initial step the E1 adenylates the C-
terminus of ubiquitin, followed by the attachment of ubiquitin to the E1 via a thioester 
bond between the carboxyl group of ubiquitin and the thiol group of the active site 
cysteine (Lee and Schindelin, 2008). The next step involves the transfer of activated 
ubiquitin to an E2, resulting in the formation of the thioester-linked conjugate. In the 
final step the E2-ubiquitin complex recruits an E3 to facilitate the transfer of ubiquitin 
to the target protein. The process culminates in the formation of a stable isopeptide bond 
between the C-terminal glycine of ubiquitin and the ε-amino group of a lysine residue in 
the target protein. In humans, ubiquitination involves two E1s, approximately 40 E2 and 
over 600 ubiquitin ligases (Jackson and Durocher, 2013). Ubiquitination is a reversible 
modification, where ubiquitin can be removed by about 100 deubiquitinating enzymes 
(DUBs). 
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Chapter 1- Introduction: Targeting post-translational modifications using fragment-based approach 
Figure 1.1 The ubiquitin system. 
Ubiquitin (Ub) is activated in the ATP-dependent step by ubiquitin-activating enzyme (E1). Activated 
ubiquitin is transferred to the active site cysteine of an E2 ubiquitin-conjugating enzyme. The E2-
ubiquitin complex interacts next with ubiquitin ligase (E3) to facilitate the transfer of ubiquitin to the 
lysine of the target protein. Multiple cycles can produce polyubiquitin chains that usually label the 
substrate for degradation by the proteasome. The process can be reversed by deubiquitinating enzymes 
(DUBs). Figure modified from Jesenberger and Jentsch, 2002. 
 
There are different types of ubiquitination (Figure 1.2). For example, the attachment of 
a single ubiquitin to the substrate is referred to as a monoubiquitination. In other 
instances, ubiquitin is attached to numerous lysines of the target protein, resulting in 
multiubiquitination. Furthermore, ubiquitin contains lysine residues within its sequence 
that can be utilised to construct polymeric chains by the sequential addition of 
individual ubiquitin moieties (Sadowski and Sarcevic, 2010). Seven internal lysine 
residues (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48, and Lys63) can be used to form 
ubiquitin chains and their length varies from two to more than ten moieties. In addition, 
there are branched ubiquitin chains as well as chains containing a mixture of ubiquitin 
and other ubiquitin-like proteins (Komander and Rape, 2012; Praefcke et al., 2012). 
Different modes of substrate modification adopt distinct structures and physical 
properties, thereby leading to different cellular outcomes. For instance, 
monoubiquitination has been shown to regulate DNA repair and gene expression 
(Passmore and Barford, 2004), while polyubiquitination using Lys48 promotes target-
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Chapter 1- Introduction: Targeting post-translational modifications using fragment-based approach 
protein degradation by the proteasome and Lys63 linked chains generally regulate 
protein-protein interactions (Jackson and Durocher, 2013). 
 
Figure 1.2 The different modes of ubiquitination.  
Ubiquitin and ubiquitin-like molecules are shown as red and green circles, respectively. Ubiquitin can be 
attached to a single (A) or multiple lysine residues (B) of the substrate. The sequential addition using the 
internal lysine residues of ubiquitin results in polyubiquitination. This produces homogeneous (C) and 
mixed ubiquitin chains (D). Branched chain (E) is produced when a single ubiquitin is modified with 
multiple molecules. Some chains contain both ubiquitin and ubiquitin-like proteins (F). Figure adapted 
from Komander and Rape, 2012. 
 
1.2.2 E3 ubiquitin ligases 
The E3 ubiquitin ligases dictate the specificity of ubiquitination by pairing with the 
substrates that are to be targeted for modification. Not surprisingly, E3s are implicated 
in a number of malignancies, making them targets for therapeutic intervention (Kirkin 
and Dikic, 2011). For example, amplification or overexpression of the gene encoding 
the mouse double minute 2, which regulates the activity of the tumour suppressor p53, 
facilitates the uncontrolled cell growth in cancer (Marine and Lozano, 2010). Breast 
cancer gene 1 encodes a tumour suppressor protein with a role in transcription and 
homologous recombination DNA repair pathway and is often mutated in familial breast 
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Chapter 1- Introduction: Targeting post-translational modifications using fragment-based approach 
and ovarian cancer (Welcsh and King, 2001). Mutations in the individual Fanconi 
anaemia proteins with the loss of the multisubunit E3 function lead to Fanconi anaemia 
and an increased risk of cancer (Moldovan and D’Andrea, 2009). Additional examples 
of the E3s that are implicated in cancer development and are of a therapeutic interest are 
discussed in detail in Lipkowitz and Weissman, 2011.    
There are two major types of E3s, classified according to their structure and mechanism 
of action. These are either a homologous with E6-associated protein C-terminus 
(HECT) domain or a really interesting new gene (RING) domain containing E3 ligases. 
In addition, a few E3s belong to a distinct U-box family, but are structurally and 
functionally similar to the RING ligases (Budhidarmo et al., 2012).  
The HECT family of ligases, which consists of about 30 members in mammals, 
participates directly in the catalytic process. HECT E3s contain an active-site cysteine 
residue that accepts ubiquitin from the E2-ubiquitin complex to form an E3-ubiquitin 
thioester conjugate (Scheffner et al., 1995). Ubiquitin is subsequently transferred from 
an E3-ubiquitin intermediate to the substrate (Figure 1.3A). HECT ligases regulate 
protein trafficking, the immune response and signalling pathways involved in cell 
growth and proliferation (Rotin and Kumar, 2009). The HECT domain, consisting of 
around 350 residues is located at the C-terminal end, while the N-terminal domain 
interacts with the target proteins. The HECT domain can be further subdivided into an 
N-terminal N-lobe that interacts with the E2 and a C-terminal C-lobe, containing the 
conserved cysteine (Huang et al., 1999). The lobes are joined by a flexible hinge, which 
brings them together during ubiquitin transfer. 
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Chapter 1- Introduction: Targeting post-translational modifications using fragment-based approach 
Figure 1.3 Comparison between HECT 
and RING E3 ubiquitination 
mechanisms.  
(A) The HECT E3s contain a conserved 
cysteine, which accepts ubiquitin prior to 
its transfer to the substrate. (B) In 
contrast, RING E3s act as scaffolds by 
bringing together E2s and substrates. 
Figure modified from Deshaies and 
Joazeiro, 2009. 
    
 
 
 
 
 
The majority of E3s belong to the RING domain family, with more than 600 potential 
RING finger E3s expressed in mammalian cells (Li et al., 2008). RING E3 ligases 
recruit together the E2-ubiquitin intermediate and the target protein to facilitate 
ubiquitin transfer directly from an E2 to the substrate (Figure 1.3B). The precise 
mechanism remains unclear, but it is believed the catalysis occurs due to the proximity 
of E2-ubiquitin and substrate (Deshaies and Joazeiro, 2009). Some studies suggest that 
the RING domain induces a conformational change in E2-ubiquitin to accelerate 
ubiquitin discharge from the active site of E2 (Seol et al., 1999; Skowyra et al., 1999). 
A canonical RING finger comprises 40-60 residues and contains a series of spatially 
conserved cysteine and histidine residues that coordinate two Zn2+ within the interior of 
the domain (Figure 1.4A; Freemont et al., 1991). However, unlike the classical DNA-
binding C2H2 tandem zinc-fingers, two Zn2+ in the RING finger are bound in a cross 
brace arrangement, yielding a compact and rigid α/β fold. The domain is stabilised 
further by semiconserved residues that form the hydrophobic core. The core region is 
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made of two β-strands (β1 and β2), one α-helix (α1) and two loops that surround the 
first and second zinc binding sites, loop 1 and loop 2 (Figure 1.4B; Budhidarmo et al., 
2012). A number of RING finger variants are known. In some the positions of cysteine 
and histidine residues are swapped, while in others the cysteine is replaced by another 
zinc coordinating residue such as aspartate (Zheng et al., 2002). The U-box E3s adopt a 
similar tertiary structure to RING E3s, even though the two have low sequence 
conservation. The U-box E3s contain polar and charged residues that form a network of 
hydrogen-bonding, thereby replacing the need for the zinc binding sites (Aravind and 
Koonin, 2000). Members of the RING E3 family can function as monomers, homo- and 
heterodimers as well as multi-subunit complexes.  
 
Figure 1.4 The RING finger domain.  
(A) The C3HC4 RING finger coordinates two Zn2+ in a cross brace structure. Cysteine and histidine 
ligands are denoted with letters C and H, respectively. Xn represents the number of any amino acids in the 
spacer regions between the zinc ligands. Figure edited from Deshaies and Joazeiro, 2009). (B) Ribbon 
diagram of the core of the RING domain from Casitas B-lineage Lymphoma protein (PDB code 2y1m; 
Dou et al., 2012). The α-helix and β-strands are coloured in purple and orange, while Zn2+ are shown as 
grey spheres. The zinc ligands are shown as sticks; with the atomic positions coloured: C (grey), N (blue) 
and S (orange). 
 
1.2.3 The Siah family 
Seven-in-absentia homolog (Siah) proteins are evolutionary conserved RING E3 
ligases. The first member, seven-in-absentia (SINA) was identified two decades ago as 
a protein required for the correct development of R7 photoreceptor cells in the 
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Drosophila eye (Carthew et al., 1990 and 1994). Further genetic and biochemical 
experiments revealed that SINA interacted with Phyllopod and the F-box protein Ebi to 
mediate the degradation of the transcriptional repressor Tramtrack88 (Ttk), thereby 
linking SINA function to protein turnover (Tang et al., 1997; Li et al., 1997; Boulton et 
al., 2000). More recently, a novel Drosophila protein was identified that shares 46 % 
sequence homology to SINA and is able to direct the degradation of Ttk (Cooper et al., 
2008). SINA homologues (Siah) were first isolated in mice and revealed three murine 
proteins, Siah1a, Siah1b and Siah2 (Della et al., 1993; Holloway et al., 1997). In 
contrast, humans contain two proteins, Siah1 and Siah2. SINA/Siah family proteins are 
highly conserved across species, except for the N-terminal 40-80 residues. For example, 
human Siah1 and Siah2 are 97 % and 98 % identical to murine Siah1a/1b and Siah2, 
and have 69 % and 67 % sequence identity with SINA, respectively. Human Siah 
proteins are 86 % homologous and 69 % identical with each other. They differ mainly at 
the N-termini with Siah2 containing an extra 42 residues.  
1.2.4 Siah1 substrates 
The Siah proteins are localised in both the nucleus and the cytoplasm and control the 
degradation of a multitude of proteins as diverse as transcriptional regulators, enzymes 
and neuronal proteins. In total, there are more than 40 known substrates. The high 
homology between Siah1 and Siah2 is reflected in a large overlap of some target 
proteins. For example, both proteins play major roles in hypoxia signalling, by 
regulating the degradation of prolyl hydroxylases (PHDs), factor inhibiting HIF1α 
(FIH) and homeodomain interacting protein kinase 2 (HIPK2) (Fukuba et al., 2008; 
Nakayama et al., 2004; Winter et al., 2008). In addition, Siah proteins have member 
specific substrates. For example, Siah2 is the predominant member that controls the 
stability of sprouty 2, involved in receptor tyrosine kinase signalling (Nadeau et al., 
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2007), while only Siah1 can polyubiquitinate the RNA polymerase II elongation factor 
(ELL2), leading to its proteasomal degradation (Liu et al., 2012). Proteins targeted for 
degradation by Siah1 are listed in Table 1.1. Siah proteins mediate ubiquitination either 
as single proteins or as part of a larger multisubunit complex.  For example, Siah1 alone 
is able to polyubiquitinate β-catenin, a key component of the Wnt signalling pathway 
controlling cell fate and proliferation, resulting in its degradation (Dimitrova et al., 
2010). However, this process is more efficient when Siah1 forms an E3 ligase complex 
with Siah-interacting protein (SIP), Ebi, the adaptor protein Skp1 and adenomatous 
polyposis coli (APC) (Matsuzawa and Reed, 2001). Therefore, not all Siah1 binding 
proteins are targeted for destruction. Some binding partners act as cofactor proteins, 
helping to recruit Siah1’s substrates, while others function as negative regulators. 
Examples of this are the scaffolding proteins Bassoon and Piccolo expressed during 
neuronal differentiation. They inhibit Siah1’s ubiquitinating activity by binding to the 
RING domain of Siah1 and preventing the interaction with E2 enzymes (Waites et al., 
2013). Siah1 binding proteins that regulate its activity and are not targeted for 
degradation are presented in Table 1.2. Structurally, little is known about how Siah1 
interacts with its binding partners and assembles into a multiprotein E3 ligase complex. 
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Substrate Protein function References 
ACK1 A non-receptor tyrosine kinase linked to cell migration, 
growth and proliferation. 
(Buchwald et al., 2012) 
AF4 Transcription factor with a role in the central nervous 
system. 
(Bursen et al., 2004) 
BOB1/OBF1 Transcriptional co-activator that regulates B-cell 
development. 
(Boehm et al., 2001) 
CBP/p300 A lysine acetyl-transferase that control cell growth, 
transformation and development. 
(Grishina et al., 2012) 
c-myb Transcriptional activator controlling cellular 
proliferation and differentiation. 
(Tanikawa et al., 2001) 
CtIP Endonuclease involved in DNA repair and cell cycle 
control. 
(Germani et al., 2003) 
ELL2 A component of the super elongation complex required 
to increase the catalytic rate of RNA polymerase II. 
(Liu et al., 2012) 
N-CoR Transcriptional co-repressor that promotes chromatin 
condensation.  
(Zhang et al., 1998) 
PML Transcriptional co-regulator found in PML-nuclear 
bodies and mediates tumour suppression, apoptosis and 
DNA damage response. 
(Fanelli et al., 2004) 
TIEG1 Transcription factor involved in the regulation of cell 
growth.  
(Johnsen et al., 2002) 
FIH A hydroxylase that functions as an oxygen sensor. (Fukuba et al., 2008) 
PHD proteins Enzymes involved in various hypoxia-influenced 
processes. 
(Nakayama et al., 2004) 
Synphilin-1 A cytoplasmic protein with the role in synaptic function 
and protein degradation and in the pathogenesis of 
Parkinson’s disease. 
(Liani et al., 2004) 
Synaptophysin A protein of the presynaptic vesicle exocytosis 
machinery. 
(Wheeler et al., 2002) 
Group1 mGluRs G protein-coupled receptors involved in many aspects 
of normal brain function. 
(Ishikawa et al., 1999) 
β-catenin Transcription factor mutated in multiple cancers.  (Liu et al., 2001; 
Dimitrova et al., 2010) 
BAG-1 Protein involved in pathways controlling cell 
proliferation and migration. 
(Matsuzawa et al., 1998) 
DCC Tumour suppressor protein with a role in mediating 
directional migration in the developing nervous system. 
(Hu and Fearon, 1999)  
EB3 Microtubule plus-end binding protein that controls 
microtubule and spindle dynamics. 
(Ban et al., 2009) 
HIPK2 Protein kinase involved in regulation of transcription 
and apoptosis.  
(Winter et al., 2008;  
Kid A nuclear protein involved in spindle formation and the 
movements of chromosomes during cell division.  
(Germani et al., 2000) 
KSHV ORF45 Human herpesvirus 8 encoded ORF45 protein is 
essential for viral infection. 
(Abada et al., 2008) 
Numb  A signalling adapter protein involved in neurogenesis. (Susini et al., 2001) 
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OGHDC A rate-limiting enzyme in the mitochondrial Krebs 
cycle. 
(Habelhah et al., 2004) 
PEG10 A mediator of apoptosis. (Okabe et al., 2003) 
PLCε Enzyme that converts polyphosphoinositides into the 
second messengers.  
(Yun et al., 2008) 
Polycystin-1 The integral membrane protein involved in renal 
tubulogenesis. 
(Kim et al., 2004) 
Tramtrack88 Transcriptional repressor involved in eye development 
of Drosophila. 
(Li et al., 1997; Tang et 
al., 1997) 
TRB3 A putative kinase that down regulates various signal 
transducers.  
(Zhou et al., 2008) 
HPH2 A subunit of a large multimeric polycomb complex 1 
implicated in the maintenance of transcriptional 
repression of target genes. 
(Wu et al., 2010) 
T-STAR Alternative splicing factor. (Venables et al., 2004) 
Table 1.1 Siah1 substrates that are targeted for proteasomal degradation. 
Abbreviations: ACK1, activated Cdc42-associated kinase 1; BOB1, B-cell Oct-binding protein; CBP, 
CREB binding protein; CtIP, C-terminal interacting protein; DCC, deleted in colorectal cancer; EB3, end-
binding protein 3; ELL2, RNA polymerase II elongation factor; FIH, factor inhibiting HIF1α; HIPK2, 
homeodomain interacting protein kinase 2; HPH2, the Homo sapiens polyhomeotic homologue 2; Kid, 
Kinesin like DNA binding protein; KSHV ORF45, Kaposi’s sarcoma-associated herpes virus open 
reading frame 45 protein; mGluRs, metabotropic glutamate receptors; N-CoR, nuclear receptor co-
repressor; OBF1, Oct binding factor 1; OGHDC, 2-oxoglutarate dehydrogenase complex; PEG10, 
paternally expressed gene 10; PHD, prolyl-hydroxylases; PLCε, phospholipase C epsilon; PML, 
promyelocytic leukaemia  protein; TIEG1, transforming growth factor β inducible early gene-1; TRB3, 
tribbles homolog 3.  
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Interacting 
protein 
Protein function References 
UbcH5, UbcH8 
and UbcH9 
E2 enzymes that accept ubiquitin from the E1 complex 
and attach it covalently to other proteins. 
(Matsuzawa et al., 2001; 
Wheeler et al., 2002; Hu 
et al., 1997) 
α-synuclein Its function is unknown.  (Liani et al., 2004) 
Dab-1 Signal transducer functioning in neural development. (Park et al., 2003) 
α-tubulin Cytoskeletal protein. (Germani et al., 2000) 
APC Tumour suppressor that promotes β-catenin degradation 
together with Siah1.  
(Liu et al., 2001) 
GAPDH Glycolytic protein that participates in transcription, 
RNA transport and apoptosis. 
(Hara and Snyder, 2006) 
PEG3 A possible transcription factor that induces apoptosis in 
cooperation with Siah1. 
(Relaix et al., 2000) 
Phyllopod  Drosophila adapter protein involved in cell 
differentiation and organ development. 
(Li et al., 2002) 
POSH  A scaffold protein of the apoptotic JNK pathway. (Xu et al., 2006) 
SIP Adapter protein involved in β-catenin degradation 
together with Siah1. 
(Matsuzawa et al., 2001) 
TRF2 A component of telomere DNA-interacting complex 
with a role in telomere maintenance. 
(Fujita et al., 2010) 
Bassoon A scaffolding protein involved in organization of 
synaptic active zones. 
(Waites et al., 2013) 
Piccolo A scaffolding protein that maintains synapse integrity 
together with Bassoon by regulating protein 
ubiquitination and degradation. 
(Waites et al., 2013) 
EEF1D Elongation factor inhibiting Siah1 ubiquitin ligase 
activity.  
(Wu et al., 2011) 
Table 1.2 Siah1-interacting proteins that are not targeted for proteasomal degradation. 
Abbreviations: APC, adenomatous polyposis coli; Dab-1, disabled-1; EEF1D, Eukaryotic translation 
elongation factor 1 delta; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PEG3, paternally-
expressed gene 3; POSH, plenty of SH3s; SIP, Siah interacting protein; TRF2, telomeric repeat-binding 
factor 2; Ubc, ubiquitin-conjugating enzyme.   
 
1.2.5 Siah1 and disease 
Siah proteins play major roles in a number of important signalling pathways, including 
Ras, hypoxia and DNA damage (Schmidt et al., 2007; Nakayama et al., 2004; Liu et al., 
2001). These pathways are often misregulated in cancer, but the exact function of Siah 
family members in tumour progression remains disputed. They were reported to be both 
oncogenic and tumour suppressive, with the initial experiments suggesting Siah1 may 
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act as a tumour suppressor. In situ hybridisation of cancerous tissue using microarrays 
revealed reduced expression levels of both Siah genes in breast cancer, and these 
correlated significantly with prognostic factors and clinical outcome (Confalonieri et 
al., 2009). Immunofluorescence microscopy studies showed that Siah1 protein levels 
were decreased in human tumour tissue compared to normal controls, suggesting Siah1 
is either a tumour suppressor or its loss is the outcome of tumour progression 
(Bruzzoni-Giovanelli et al., 2010). Studies in hepatoma cells revealed that low levels of 
Siah1 correlated positively with reduced apoptosis, while over-expression of Siah1 in 
293 epithelial cells and GM701, an SV40-transformed human fibroblast cell line led to 
growth arrest (Yoshibayashi et al., 2007; Matsuzawa et al., 1998). Further studies 
observed enhanced radiosensitivity of human breast cancer cells upon overexpression of 
Siah1 (He et al., 2010). The above mentioned studies allude to a tumour suppressive 
function of Siah1. However, proteins acting as tumour suppressors are often mutated in 
cancer, but currently there is little evidence of that for Siah1. Two missense mutations, 
occurring at a low frequency in gastric cancer have been reported so far, resulting in 
stabilisation of oncogene β-catenin and apoptosis block, while no mutations were 
identified in another study looking at other cancer types (Kim et al., 2004; Medhioub et 
al., 2000). A more recent study observed that nuclear accumulation of Siah1 enhanced 
proliferation and migration of hepatocellular carcinoma cells, suggesting Siah1 is pro-
tumourigenic (Brauckhoff et al., 2011). In addition, a number of studies that did not 
differentiate between Siah family members were performed using the animal cancer 
models and their data uniformly support an oncogenic role of Siah proteins (Schmidt et 
al., 2007; Möller et al., 2009). Together these studies depict an opposing mix of results 
and additional experiments are required to establish the role of Siah1 in tumour 
progression. 
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1.2.6 Siah1 as a drug target 
Given the importance of Siah proteins as master regulators of different signalling 
pathways and their relevance in cancer development, they may be useful therapeutic 
targets. Siah proteins contain an N-terminal RING domain, two zinc finger motifs and a 
C-terminal substrate binding domain (SBD) (Figure 1.5A). They are dimeric proteins, 
with the region in SBD involved in dimerisation. Three structures of Siah1 SBD without 
the RING domain have been determined, with the highest resolution of 2.20 Å (Figure 
1.5B). Siah proteins have three main sites for inhibition, resulting in potentially 
different biological effects. These are the disruption of protein-protein interactions 
between Siah and either substrate, E2 enzyme or another Siah subunit in a dimer. The 
first inhibitor identified to target Siah function was the PHYL peptide. This peptide, 
containing a 23 residue sequence from phyllopod protein is a potent binder of Siah SBD 
and was shown to reduce the tumour growth and metastasis in a number of models 
(House et al., 2003; Möller et al., 2009; Qi et al., 2010). Inhibitors targeting Siah SBD 
may be specific for these proteins, but they may not distinguish between the two Siah 
isoforms due to their high homology in this region. The N-terminal RING domain of 
Siah is essential for their ubiquitinating activity. RING domain mutants of Siah abrogate 
substrate degradation and impair with Ras signalling pathway, thereby interfering with 
cancer progression (Hu and Fearon, 1999; Wong and Möller, 2013). Inhibitors may be 
designed to target N-terminus/RING domain to block the binding of E2. The N-terminal 
regions vary between Siah1 and Siah2; thereby isoform selective inhibitors may be 
designed (Della et al., 1993). However, RING domain inhibitors may also impair with 
the function of other RING-containing E3 ligases. A third method to interfere with Siah 
activity would be to disrupt its dimerisation interface. Protein Zyxin involved in the 
regulation of actin cytoskeleton dynamics and cell motility was identified recently to 
inhibit Siah1 homodimerisation (Crone et al., 2011). However, further studies are 
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needed to elucidate the impact of Siah homo- and heterodimerisation and the outcome 
of disrupting such interactions in cancer. Proof of concept for small molecule inhibitors 
targeting Siah was obtained with menadione (vitamin K12). It was initially identified to 
inhibit Siah2 in a screen of U.S. Food and Drug Administration approved therapeutic 
drugs using electro-chemiluminescent-based assay (Shah et al., 2009). Further in vitro 
based dose-response experiments looking at Siah self-ubiquitination also showed the 
inhibition of Siah1. The same paper reports that menadione blocked the Ras/mitogen-
activated protein kinase pathway, attenuated hypoxia and inhibited melanoma 
tumourigenesis. Although the inhibitory mechanism of menadione is not known, this 
study supports the rationale for screening for inhibitors of Siah.  
Figure 1.5 Structure of Siah.  
(A) Schematic diagram shows the 
domain architecture of Siah. The 
main difference between Siah1 and 
Siah2 is in the length of the N-
terminal sequence prior to the 
RING domain. (B) The structure of 
Siah1 SBD determined to 2.20 Å 
(PDB code 2a25; Santelli et al., 
2005). SBD and the adjacent zinc 
finger motif are coloured in green 
and marine, respectively. Zn2+ is 
shown as a grey sphere and the 
disordered loops are marked with 
asterisks. A 13 residue peptide 
containing a conserved VxP motif 
present in many substrates of Siah 
is shown in yellow. 
       
 
1.3 SUMOylation 
In addition to ubiquitin, there are a number of ubiquitin-like proteins that can be 
conjugated to the target proteins. One of them is small ubiquitin-like modifier (SUMO), 
which was first observed to modify the nucleoporin Ran GTPase-activating protein 1 
(RanGAP1) leading to its translocation (Matunis et al., 1996; Mahajan et al., 1997). 
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Later studies revealed that SUMO participated in a wide variety of cellular processes 
including cell cycle control, gene transcription, cellular localisation, degradation and 
chromatin organisation (Müller et al., 2001; Seeler and Dejean, 2003; Verger et al., 
2003). However, its primary molecular role is to regulate interactions of the modified 
substrates with other proteins. SUMO (~100 residues, ~8 kDa) shares only 18 % 
sequence identity with ubiquitin, but structural studies by nuclear magnetic resonance 
(NMR) revealed the overall structure closely resembles that of ubiquitin, characterised 
by a tightly packed globular fold with β-sheets wrapped around one α-helix (Bayer et 
al., 1998; Müller et al., 2001). Lower eukaryotes such as yeast contain a single isoform 
of SUMO, while mammals have three homologues (SUMO-1, -2 and -3), in contrast to 
a single type of ubiquitin. SUMO-1 is 50 % identical to SUMO2/3, while the later share 
95 % homology and appears to be functionally redundant (Johnson, 2004). Analysis of 
the protein sites modified by SUMO, revealed that conjugation occurs on the lysine 
residue present in the ψKxE sequence, where ψ corresponds to a large hydrophobic 
amino acid and x represents any amino acid (Rodriguez et al., 2001). This consensus 
motif is also found at the N-terminus of SUMO2/3, allowing them to form polySUMO 
chains. The motif is absent from SUMO-1, thereby it is unable to form polymers and 
functions as a polySUMO chain terminator (Kroetz, 2005; Ulrich, 2009). The SUMO 
conjugation mechanism is similar to the ubiquitination pathway. It requires ATP and a 
cascade of three enzymes. SUMO-activating enzyme (E1) activates the SUMO C-
terminal carboxyl group followed by formation of a thioester conjugate. The SUMO is 
subsequently transferred to the active site cysteine residue of the SUMO-conjugating 
enzyme (E2). The final transfer of SUMO to the target protein is generally mediated by 
SUMO ligases, which bring E2-SUMO complex and substrate together, thus enhancing 
SUMOylation (Ulrich, 2009). In contrast to a large variety of enzymes participating in 
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ubiquitination process, SUMOylation uses only a single E1, one E2 and about ten E3s 
(Yeh, 2009). SUMOylation can be reversed by SUMO-specific proteases (SENPs).  
1.3.1 The SENP family 
SENPs perform two functions; deconjugate SUMO moieties from the modified proteins 
and catalyse the maturation of SUMO precursors. The SUMO genes produce precursor 
proteins, which are subsequently processed by SENPs into a mature form by cleaving 
the peptide bond to expose the C-terminal diglycine motif (Figure 1.6A). This form of 
SUMO is then linked via its carboxyl group with the ε-amino group of a lysine in the 
substrate, forming an isopeptide bond. This bond can be later cleaved by the 
isopeptidase activity of SENPs to release the target protein and SUMO back into the 
SUMO conjugation cycle (Figure 1.6B). Thus, SENPs initiate the SUMOylation cycle 
by regulating the availability of free SUMO and also control the modification status of 
individual substrates. SENPs belong to the C48 protease family that shares a conserved 
catalytic domain with a characteristic catalytic triad of histidine, aspartate and cysteine 
(Yeh et al., 2000). Humans contain six SENPs, which can be divided into three groups. 
The first group contains SENP1 and SENP2, which are involved in both precursor 
processing and deconjugation of all three SUMO isoforms. SENP3 and SENP5 belong 
to the second group. They are found in the nucleolus and appear to specialise in the 
proteolysis of SUMO2/3 (Hickey et al., 2012). The third group includes SENP6 and 
SENP7, which are localised in the nucleoplasm and involved in the editing of 
polySUMO2/3 chains (Hattersley et al., 2011; Shen et al., 2009).        
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Figure 1.6 Isopeptidase and endopeptidase activities of SENPs.  
(A) The cleavage at the C-terminal end of SUMO results in its mature form. Diagram shows the C-
termini of three mammalian SUMO isoforms, with the diglycine motif coloured in green. The chemical 
structure of the C-terminal end of SUMO1 is presented, with the site of cleavage marked within a box and 
the scissile bond being cleaved indicated by an arrow. (B) SUMO deconjugation from the target protein. 
The chemical structure of the isopeptide bond between target lysine and SUMO is shown. The site of 
cleavage is indicated with a box and an arrow points to the isopeptide bond.  
         
1.3.2 SENP1 
SENP1 has a broad specificity, processing three pro-SUMO isoforms to their mature 
form and deconjugating them from modified proteins (Xu and Au, 2005; Gong et al., 
2000). It contains the C-terminal catalytic domain and the N-terminal localisation 
region (Figure 1.7A). The later contains a nuclear localisation signal, targeting SENP1 
to the nucleoplasm (Gong et al., 2000). Crystal structures of the apo-SENP1 and SENP1 
in complex with either pro-SUMO1 or SUMO1-modified RanGAP1 reveal its catalytic 
region and the mechanism of action (Shen et al., 2006). SENP1 shares a common fold 
with other SENPs, in which the core is made of a five stranded mixed β-sheet situated 
adjacent to two α-helices (Figure 1.7B). The conserved His533 and Asp550 are situated 
on two neighbouring β-stands, with Cys603 located on a central α-helix. Analysis of the 
structure of SENP1 bound to SUMO1-RanGAP1 indicates the minimal recognition of 
the substrate, with the main interface area formed between the conserved C-terminal 
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strands of SUMO1 and the main chain of SENP1. Structural studies also suggest that 
the binding of SUMO precursors and SUMO-target conjugates to SENP1 results in the 
opening of a tunnel to accommodate diglycine motif (Yeh, 2009). This tunnel is formed 
by two tryptophan residues and is too narrow to fit residues other than glycine. Closing 
of the tunnel then leads to trans, cis-isomerisation of the amide nitrogen atoms of the 
scissile bond. The resulting cis peptide bond is thermodynamically unfavoured and 
promotes cleavage (Hickey et al., 2012). 
 
Figure 1.7 Structure of SENP1. 
(A) Domain organisation of SENP1. (B) The stereo image is showing the catalytic domain of SENP1 
determined to 2.45 Å (PDB code 2iyc; Shen et al., 2006). The α-helices and β-strands are coloured in 
purple and orange, respectively. A catalytic triad is shown as sticks, with the atomic positions coloured: C 
(grey), N (blue), S (yellow) and O (red). 
 
 
SENP1 is overexpressed in prostatic intraepithelial neoplasia and prostate cancer 
lesions, and promotes androgen receptor dependent transcription and cell proliferation 
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(Bawa-Khalfe et al., 2007; Kaikkonen et al., 2009). Silencing of SENP1 attenuates the 
expression of several AR target genes and reduces androgen-stimulated growth of 
LNCaP cells (Kaikkonen et al., 2009). These data suggest that SENP1 could play an 
important role in prostate carcinogenesis. Development of small synthetic inhibitors is 
currently underway to validate SENP1 as a potential drug target (Uno et al., 2012; Chen 
et al., 2012; Sommer et al, 2013; Madu et al., 2013).  
1.4 Introduction to fragment screening  
1.4.1 Fragment based drug discovery 
A typical collection of compounds employed for high throughput screening (HTS) in 
the 1990s consisted of molecules with at least 15 heavy atoms (Tounge and Parker, 
2011). The identified hits had to be subsequently optimised to include the desirable 
absorption, distribution, metabolism, excretion and toxicity properties (Jhoti, 2005). 
However, as the size of the initial hits was already similar to the common drug 
molecules, the scope for optimisation was limited and these compounds often failed at 
the later stage of drug development. 
A survey, looking at the physico-chemical properties of known orally available drugs, 
resulted in a set of parameters known as the Lipinski rule of five, which improved the 
likelihood of compounds being membrane permeable and easily absorbable by the body 
(Table 1.3; Lipinski et al., 2001). These rules were widely implemented due to their 
simplicity to assess not only the oral bioavailability, but also overall drug-likeness of 
compounds. Although some drugs did not obey the rules, they still raised the awareness 
for such properties (Wenlock et al., 2003). In particular, the lead-like molecules were 
re-evaluated with a view of retaining their properties during the later stages of 
23 
 
 
Chapter 1- Introduction: Targeting post-translational modifications using fragment-based approach 
optimisation. This meant setting tighter restrictions on their chemical properties, such as 
limiting their molecular weight to <400 Da (Leach and Hann, 2011).  
Property Lipinski rule of five Rule of three 
Mw <500 <300 
H-bond donors ≤5 ≤3 
H-bond acceptors ≤10 ≤3 
ClogP =5 =3 
Table 1.3 Comparison of Lipinski rule of five to rule of three.  
Data taken from Lipinski et al., 2001 and Congreve et al., 2003. 
     
More recently, a new approach of using even smaller molecules termed fragments 
became popular. Fragments have lower molecular weight and generally contain fewer 
functional groups, with most fragment libraries complying with properties outlined by 
the rule of three (Table 1.3; Congreve et al., 2003). Fragments contain a number of 
unique properties that distinguish them from typical HTS compounds. Firstly, fragments 
have higher probability of binding due to fewer interaction constraints. For example, 
many proteins contain cavities, which are able to accommodate a simple structure like a 
phenol ring with single hydrogen bond donor. However, a more specific binding site is 
needed to fit a compound with three hydrogen bond contacts while maintaining good 
van der Waals contacts and ligand geometry (Tounge and Parker, 2011). Therefore, the 
likelihood of compound binding goes up as its complexity goes down (Hann et al., 
2001). Evidence of this can be observed in the high ligand efficiencies detected for 
fragments, which are at least as high as those for larger hit-molecules (Bembenek et al., 
2009; Nissink, 2009). Ligand efficiency (LE) measures the binding affinity per heavy 
atom (non-hydrogen) (Hopkins et al., 2004): 
𝐿𝐸 = ∆𝐺!"#$"#%#𝐻𝐴 = −𝑅𝑇𝑙𝑛𝐾!#𝐻𝐴  
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where #HA is the number of heavy atoms, ∆Gbinding (Gibbs free energy), R the gas 
constant, T the absolute temperature and Kd the dissociation constant. 
Secondly, drug-like compounds of HTS size (350-550 Da) can theoretically produce 
over 1060 unique combinations, but an estimated number of possible molecules 
composed of 11 or fewer heavy atoms is about 107 (Bohacek et al., 1996; Ertl, 2003). 
Therefore, a smaller library of about 103 fragments can explore a significantly larger 
volume of chemical space compared to the usual HTS collection of 106 larger 
compounds. In addition, smaller libraries reduce the screening and compound synthesis 
time. Fragments are also likely to show less prejudice for specific target classes, as 
many corporate HTS collections contain compounds with tendency to hit kinases for 
example (Tounge and Parker, 2011), although criteria used in library design will always 
influence their final applicability.  
1.4.2 Fragment screening 
Fragments generally have binding affinities for the target protein in the range of 0.1-10 
mM. Detection of such weak binding requires sensitive screening methods. In addition, 
the screen is performed at higher concentrations of fragments than those employed in 
typical HTS biochemical assays. Figure 1.8 depicts the range of methods available for 
fragment screening. The screening methods can be divided into two groups. Traditional 
biophysical methods such as Surface Plasmon Resonance (SPR) and Differential 
Scanning Fluorimetry (DSF) only detect binding, while the second group that includes 
protein-detection NMR and X-ray crystallography offer further information about the 
binding site. Most screening techniques provide various degree of affinity information. 
Traditional techniques have a high throughput format and are often used in the initial 
fragment screen, which can be later followed up by the structural method to reveal 
binding interactions. In all fragment based drug discovery studies, structural 
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information is desirable to progress hits towards compounds with higher efficacy and 
selectivity, known as leads. The screening techniques are discussed in more detail in the 
later chapters.   
Figure 1.8 Examples of various 
fragment-screening techniques.  
(A) Thermal shift assay monitors 
changes in the melting temperature due 
to ligand binding. (B) Mass 
spectrometry is used to detect protein-
ligand interactions directly. (C) 1D 
NMR is generally used for screening 
and 2D NMR for further hit 
characterisation. (D) SPR sensorgrams 
depict a fragment titration experiment. 
(E) X-ray crystallography can provide 
information about the fragment binding 
site. (G) Virtual screening is a 
computational method of fragment 
screening. Figure adapted from Scott et 
al., 2012.  
 
 
 
 
 
 
 
 
 
Validated fragment hits are optimised to enhance their potency using rational design 
coupled with the cycles of structural studies and affinity data measurements (Scott et 
al., 2012). Approaches employed for fragment optimisation fall into three groups: 
fragment merging, linking and growing. Fragment merging involves the incorporation 
of different regions of overlapping molecules into a single compound. In fragment 
linking, the separate molecules binding at non-overlapping sites are joined together. 
Fragment growing is a frequently used method, where molecules are modified using 
chemical synthesis to include additional binding contacts (Hubbard, 2008).  
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1.5 Aims 
Siah1 and SENP1 represent crucial regulators of a number of signalling pathways and 
have been shown to facilitate cancer progression and spread (Wong and Möller, 2013; 
Yeh, 2009). Therefore, they could be attractive targets for therapeutic intervention. 
Development of inhibitors is currently underway, with a number of virtual screening 
studies reporting inhibitors of SENP1 (Madu et al., 2013). Long inhibitory peptides 
mimicking the substrate have been reported for Siah1 and demonstrated the desirable 
effect in cells (House et al., 2003). These early compounds provide a proof-of-concept 
for screening for novel inhibitors with better efficacies. 
Fragment screening has emerged as a complementary and contrasting approach to HTS 
to identify the starting leads. There are a number of drug candidates developed using 
this method that are currently in the clinical trials, thereby supporting the power of this 
method (Scott et al., 2012). The methodology proved successful against the initial 
targets such as kinases and phosphatases, and it is now being diversified to include more 
challenging classes of targets. The main aims of the work described in this thesis were 
to assess the applicability of the fragment screening for targeting protein-protein 
interactions and cysteine proteases such as Siah1 and SENP1, respectively. Protein-
protein interactions generally differ from protein-ligand binding sites. They form an 
extensive interface with multiple contacts in contrast to a single profound cavity found 
in most protein-ligand active sites. Analysis of the contributions of individual residues 
in protein-protein interactions revealed the free energy of binding is not distributed 
evenly and observed the hot spots enriched in tryptophan, tyrosine and arginine (Bogan 
and Thorn, 1998). A number of studies discovered small molecule inhibitors with drug-
like potencies that targeted these hot spots (Wells and McClendon, 2007). However, 
further studies are required to assess protein-protein interactions that involve other 
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protein folds and contain a different set of interface residues. There are a number of 
SENP inhibitors available, but more potent and isoform selective inhibitors are required 
(Madu et al., 2013). SENP1 might be amenable to a fragment-based approach to 
identify molecules targeting its shallow active site and those that distinguish the active 
site’s unique features. 
Another objective was to probe the characteristics of different screening methods. Any 
fragments identified in the process would be advantageous for elucidating the roles of 
these proteins in post-translational processes as well as validating them as therapeutic 
targets, and might even serve as starting points for drug-development in the future. Two 
fragment libraries were screened using DSF and SPR methods. The outcomes of these 
fragment screens and the limitations of different screening methods are reported and 
discussed in chapters three and four for Siah1 and SENP1, respectively.    
Siah1 is a scaffolding protein interacting with its target proteins to facilitate their 
ubiquitination and subsequent degradation (Table 1.1). It also interacts with many non-
substrate proteins that regulate its activity and sometimes forms the multiprotein E3 
ligase complexes to mediate ubiquitination of certain substrates (Table 1.2; Matsuzawa 
and Reed, 2001). A number of substrates have been shown to bind Siah1 via a 
conserved VxP motif and a few NMR studies analysed the interaction sites using short 
protein fragments (House et al., 2006; Santelli et al., 2005). However, this information 
is absent for majority of Siah1-binding proteins and no structural data are available to 
understand the formation of Siah1 ligase complexes. Furthermore, some published 
studies reporting the novel substrates of Siah1 are not conclusive and additional 
experiments are needed to validate them. Chapter five covers protein interaction studies. 
A number of previously reported Siah1-binding proteins were evaluated with the aim to 
elucidate the precise binding mechanism.   
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2.1 General materials  
2.1.1 Reagents 
General reagents were purchased from suppliers Sigma-Aldrich, BDH Chemicals and 
Fisher unless otherwise stated. Tobacco etch virus (TEV) protease with a polyhistidine-
tag was prepared by Keri Barrack (University of Dundee) and stored at -80 oC until 
required. 1 mg of TEV protease was used per 20 mg of protein in a cleavage reaction, 
which was performed at room temperature for three hours. NuPAGE 10 % Bis-Tris and 
Mini-PROTEAN TGX precast gels as well as premixed electrophoresis running buffers 
were purchased from Invitrogen and Bio-Rad, respectively. DNA and protein ladders 
were HyperLadder I (Bioline) and SeeBlue Plus2 Pre-stained Standard (Invitrogen). 
Coomassie Brilliant Blue and InstantBlue (Expedeon) were used to stain the protein 
gels. 
2.1.2 Bacterial strains and growth media 
TOP 10 competent cells (Invitrogen) and XL1 blue competent cells (Stratagene) were 
used for DNA preparation. Escherichia coli Bl21 (DE3) Gold cells (Novagen) were 
used for expression of all protein constructs. Luria-Bertani (LB; Bertani, 1951) broth 
and LB-agar plates were purchased from the College of Life Sciences Media Kitchen 
(University of Dundee). Super optimal broth with catabolite repression (S.O.C.) 
medium (Invitrogen) was used for bacterial transformations. 
2.1.3 Peptide inhibitors  
Two synthetic peptides were purchased from commercial sources to be used as the 
positive control in the SPR fragment screen (Table 2.1). 
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Sequence Molecular 
weight 
Purity Commercial 
source 
Ala-Ser-Leu-Gln-Arg-Val-Arg-Arg-Pro-Val-Ala-
Met-Val-Met-Pro-Ala-Arg-Arg-Thr-Pro-His-Val-
Gln (plectin-195-117 peptide) 
2697 Da >95 % Cambridge 
Research 
Biochemicals 
Arg-Pro-Val-Ala-Ala-Val-Arg-Pro-Thr 966 Da >98 % GenScript 
Table 2.1 Peptide inhibitors. 
2.2 Molecular cloning 
2.2.1 Protein constructs and expression plasmids 
The proteins used for this work (unless mentioned otherwise) are given in the Table 
2.2. The gene encoding SENP1 in a pHISTEV30a vector was a kind gift of Ron Hay 
(University of Dundee). The gene fragments encoding Siah1, SIP and PEG3 with 
flanking restriction sites were purchased in the pUC57 vector (GenScript). These were 
subsequently cut out using appropriate restriction enzymes and ligated into the pET15b-
TEV vector. Thomas Eadsforth (University of Dundee) cloned the BcCCP gene from 
genomic DNA into the pET15b-TEV vector. The pET15b-TEV and pHISTEV30a 
plasmids encode genes conferring resistance to carbenicillin and kanamycin, 
respectively. Both plasmids are designed to express the protein of interest with an N-
terminal hexa histidine tag and a TEV protease cleavage site.  
Protein Residues UniProt No. 
SENP1 415-644 Q9P0U3 
Siah1 91-282 Q8IUQ4 
SIP 1-228 Q9HB71 
PEG3 40-130 Q9GZU2 
BcCCP 1-384 B4EEQ5 
Table 2.2 Protein constructs. 
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2.2.2 DNA manipulation 
Other gene fragments encoding alternative, shorter protein constructs were generated 
using polymerase chain reaction (PCR). The technique involves repeated cycles of 
heating and cooling to amplify the desired DNA sequence. The heating is required to 
separate the DNA strands, while the cooling allows the primers to anneal, before the 
extension of the primed strands can proceed. Synthetic genes, mentioned in section 
2.2.1, were used as DNA templates to generate shorter gene fragments. Primers were 
purchased from Thermo Fisher Scientific. The PCR reactions were carried out using 
parameters outlined in Table 2.3 and using Perkin-Elmer GeneAmp PCR Systems 2400 
and 2700. The amplified PCR products were initially ligated into PCR-BluntII-TOPO® 
vector (Invitrogen), before being cut and ligated into similarly digested pET15b-TEV 
expression vector using T4 DNA ligase. The restriction enzymes (BamHI, EcoRI and 
XhoI), Pfu DNA polymerase and T4 DNA ligase were purchased from New England 
Biolabs. All DNA preparations (plasmid minipreps and agarose gel extractions) were 
performed using Qiagen kits and protocols. DNA concentrations were measured by 
absorbance at 260 nm with the NanoVue™ spectrophotometer (GE Healthcare). DNA 
constructs were verified by DNA sequencing (DNA Sequencing Unit, University of 
Dundee).   
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Component Volume (µL) Step Cycling conditions 
Pfu DNA Polymerase buffer 
10X 
5 A. Initial denaturation 94 oC for 5 minute 
dNTPs (10 mM) 1 B. Denaturation 95 oC for 1 minute 
Forward primer (10 pmol/µL) 2      Annealing 44-65 oC for 1 minute 
Reverse primer (10 pmol/µL) 2      Extension 72 oC for 2 minute/kbp 
Template DNA Variable (< 25 ng) C. Final extension 72 oC for 10 minutes 
Pfu DNA polymerase                   
(1 unit/µL) 
1 D. Soak 4 oC indefinite 
Milli-Q water To 50 Step B 30 cycles 
Table 2.3 Standard PCR parameters and cycling conditions. 
2.3 Protein expression 
The recombinant proteins were expressed in E. coli (for strain details see section 2.1). 
Bacteria were transformed by mixing 15 µL competent cell culture with 1 µL plasmid 
DNA. The cells were left on ice for 20 minutes, before heat shocking at 42 oC for 45 
seconds and cooling on ice for another 2 minutes. 100 µL of S.O.C. broth were added 
and the cells were incubated in a shaker at 37 oC for one hour, before plating the cells 
on the agar plate containing the appropriate antibiotic. For protein expression, a single 
colony was picked from a fresh transformation plate and incubated in 10 mL of LB 
supplemented with antibiotic at 37 oC overnight. The next morning, the appropriate 
volume of seeder culture was added to 1 L antibiotic supplemented LB to get a starting 
OD600 of 0.05. The cells were incubated at 37 oC with shaking until OD600 reached 0.6. 
Expression was induced with 0.2 mM IPTG. In brief, the expression plasmids contain 
the constitutive lacI gene encoding the repressor protein LacI that binds the lac operon 
engineered upstream of the gene of interest and inhibits its transcription. When IPTG is 
present, it binds to the repressor and displaces it from the lac operon thereby allowing 
T7 RNA polymerase to initiate transcription. Upon addition of IPTG, cells were grown 
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overnight at 22 ºC and harvested by centrifugation at 3500 g (Beckman J6-MC with a 
JA6 rotor) for 30 minutes at 4 oC. The supernatant was discarded and the bacterial pellet 
was resuspended in approximately 20 mL of buffer (A, C or D; Table 2.4), prior to the 
storage at -20 oC until further use.  
2.4 Protein purification 
Frozen cell pellets were defrosted at room temperature, followed by addition of DNase I 
(0.1 mg) and a single tablet of a cocktail of EDTA-free protease inhibitors (Roche). 
Cells were lysed using the French Press (American Instrument Company) at 16,000 psi. 
Insoluble debris was separated by centrifugation at 37,500 g (Beckman Avanti J-25 with 
JA25.50 rotor) for 30 min at 4 °C. The soluble fraction was filtered through a 0.2 µm 
Minisart® membrane (Sartorius) and loaded onto a 5 mL Ni2+-charged HisTrap HP 
column (GE Healthcare), preequilibrated with buffer (A, C or D; Table 2.4). A linear 
imidazole concentration gradient was applied using buffer (B or E; Table 2.4) to elute 
the protein of interest. The collected fractions were analysed on polyacrylamide gels. 
Fractions containing the recombinant protein were pulled together and dialysed in 
buffer (C or F; Table 2.4) to remove imidazole. TEV protease, which recognises the 
Glu-Asn-Leu-Tyr-Phe-Gln-Gly sequence and cleaves the peptide bond between Gln and 
Gly, was added to remove the N-terminal histidine tag. After TEV digestion, the protein 
was passed through a second nickel-affinity column to remove uncleaved protein. 
Eluted protein was concentrated using Vivaspin and Amicon Ultra concentrators 
(Sartorius and Millipore) with appropriate MW cut off and then loaded onto a gel 
filtration column (Superdex 75 16/60 or Superdex 200 26/60; GE Healthcare) for the 
final purification step. The columns had previously been calibrated with molecular 
weight standards, thyroglobulin (670 kDa), γ-globulin (158 kDa), ovalbumin (44 kDa), 
myoglobin (17 kDa), and vitamin B12 (1.35 kDa) (Bio-Rad). All protein purifications 
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were performed using ÄKTA systems (Explorer, Purifier and Prime; GE Healthcare). 
SDS-PAGE gel and matrix assisted laser desorption ionization time-of-flight (MALDI-
TOF) mass spectrometry (Fingerprint Proteomics Facility, University of Dundee) were 
used to check the final sample purity. Protein concentrations were determined 
spectrophotometrically using the theoretical molar extinction coefficients calculated 
with ProtParam (Gasteiger et al., 2005).  
Name Buffer Used for the purification 
of 
A 50 mM Tris-HCl, pH 7.5, 250 mM NaCl, 20 mM imidazole SENP1 
B 50 mM Tris-HCl, pH 7.5, 250 mM NaCl, 1 M imidazole SENP1, BcCCP* 
C 50 mM Tris-HCl, pH 7.5, 250 mM NaCl SENP1, BcCCP* 
D 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 20 mM imidazole Siah1, SIP, PEG3 
E 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 M imidazole Siah1, SIP, PEG3 
F 50 mM Tris-HCl, pH 7.5, 150 mM NaCl Siah1, SIP, PEG3 
Table 2.4 Buffers for protein purification. 
*Initially, BcCCP protein was expressed and purified by Thomas Eadsforth (University of Dundee). 
 
2.5 Protein structure determination by X-ray crystallography 
2.5.1 Protein crystallisation theory 
The crucial step in structural crystallography is to grow X-ray quality crystals. 
Crystallisation is a phase separation phenomenon. When the protein molecules are fully 
solvated, the system is at the state of equilibrium. However, as the number of molecules 
in solution increased, the supersaturated state is reached where there is insufficient 
solvent to maintain full hydration of the molecules. At this point, the molecules come 
out of solution to form either an amorphous precipitate or crystal nuclei thereby 
returning the system to thermodynamically favoured equilibrium (Weber, 1991). 
Precipitating agents are used to achieve protein supersaturation. The popular reagents 
include salts, which diminish electrostatic repulsion between proteins, and PEGs, which 
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compete for water molecules with proteins. Other factors affecting crystallisation 
include purity and concentration of macromolecule, pH, ionic strength and temperature.     
2.5.2 Crystallisation techniques 
The physical technique used in the study presented in this thesis to achieve 
supersaturation in protein solutions was vapour diffusion; in particular the hanging and 
sitting drop variations (Figure 2.1). This method relies on evaporation and diffusion of 
a volatile component (typically water) between solutions of different concentrations 
until the thermodynamic equilibrium is reached. In the initial step, the sample drops 
were prepared by mixing protein solution with a similar volume of precipitant solution. 
Generally, 1-3 µL and 0.1-0.5 µL of protein solution were used to prepare hanging and 
sitting drops, respectively. The drops were then suspended and sealed over a reservoir 
containing precipitant and/ or desiccant solution. The volumes of the reservoir solution 
were 1 mL and 60 µL for hanging and sitting drop, respectively. The higher 
concentration of precipitant in the well solution causes water molecules to travel from a 
drop into the reservoir until the concentration becomes equal. Over time, the precipitant 
and protein concentrations in a drop increase until a nucleation region is reached at 
supersaturated state. As the first crystals are formed the protein concentration is reduced 
and the system enters the metastable region, which allows crystals to grow, but does not 
support nucleation. Crystal growth proceeds until the protein solution becomes 
undersaturated.    
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Figure 2.1 Vapour diffusion techniques.  
The image shows vapour diffusion methods used in this study. Initial high-throughput screening was done 
using sitting drop method and the subsequent hit conditions where optimized using the hanging drop 
method.  The blue and grey shapes represent protein crystallisation drop and reservoir solution, 
respectively.  
 
2.5.3 Crystallisation strategy 
It is hard to predict specific crystallisation conditions for a particular protein and 
numerous experiments are usually required to identify the best crystallisation 
conditions. However, modern robotics allows many crystallisation parameters to be 
screened in a short time, while consuming the minimum amounts of protein. The high-
throughput Phoenix liquid handling system (Art Robbins Instruments/ Rigaku) was 
employed to screen several hundreds of individual crystallisation conditions known as 
sparse matrix screens. These were purchased from commercial sources and included 
Classic, PEG, MPD, AmSO4 suites from Qiagen and JCSG+, PGA suites from 
Molecular Dimensions. Crystallisation conditions were screened in 96-well plates using 
a sitting drop method. The lead conditions determined from the initial screen were 
optimized further to produce better diffraction quality crystals. This was done manually 
in 24-well plates by varying different parameters in small steps and using larger 
volumes. Optimisation step employed a hanging drop method.  
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2.5.4 X-ray diffraction from crystals 
Details on the theory of protein structure determination mentioned in this section can be 
found in Biomolecular Crystallography (Rupp, 2010). Structure determination by X-ray 
crystallography relies on the scattering of X-rays by the electrons found in the 
molecules of a crystal. The crystal acts as a three-dimensional (3D) diffraction grating, 
scattering the X-ray beam in many directions. However, diffracted beams called 
reflections of measurable intensity are only observed when the scattered waves add up 
in phase. In other directions the waves are out of phase and cancel one another out. 
Bragg’s law, which treats crystals as sets of equally spaced parallel planes running in 
different directions, describes the conditions necessary for constructive interference to 
occur (Figure 2.2). Bragg’s law, expressed as nλ=2d sinθ, relates the wavelength of X-
ray beam (lambda, λ) to the diffraction angle (theta, θ) and the lattice spacing within a 
crystal (d). It states that waves scattered from successive planes add up constructively 
when the difference in the distance travelled by two equals to an integer (n) number of 
wavelengths.  
 
Figure 2.2 Bragg’s law.  
The constructive interference is observed when the path difference between two waves scattered from 
adjacent planes, which is 2d sinθ, equals to an integer number of wavelengths nλ. Figure modified from 
www.microscopy.ethz.ch/bragg.htm. 
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2.5.5 X-ray sources 
The common X-ray sources for a diffraction experiment are rotating anode generators 
and synchrotrons. Both were used to collect the diffraction data presented in this thesis. 
In an X-ray generator, the electrons emitted by the cathode are accelerated towards the 
anode and produce X-rays upon the impact. The material of the anode determines the 
wavelength of the generated X-rays. In-house generators often use the copper anode, 
producing CuKα radiation of λ=1.5418 Å. Filters, monochromators or X-ray mirrors are 
applied to get monochromatic X-ray beam focused onto the crystals. At a synchrotron 
facility, the X-ray radiation is generated by the beam of electrons travelling in a 
continuous loop with the help of the magnets. The advantage of using a synchrotron is 
that it produces a tunable and much more intense X-ray source than a rotating anode 
generator.  
2.5.6 Structure determination  
The goal of a crystallographic experiment is to obtain the electron density distribution, 
which is subsequently used to assign the atomic coordinates. The electron density map 
p(xyz) has the following expression:  
𝑝(𝑥𝑦𝑧) = 1𝑉 F!!" (ℎ𝑘𝑙)exp[− 2𝜋i(ℎx+ 𝑘y+ 𝑙z)] 
where F(hkl) are the structure factors, V is the unit cell volume and h, k, l are the Miller 
indices. The electron density can be calculated from the structure factors by applying a 
mathematical operation called Fourier transform. Each structure factor F(hkl) is a 
complex number composed of reflection amplitude |F(hkl)| and its phase α(hkl) with the 
relationship: 
F ℎ𝑘𝑙 = 𝐹ℎ𝑘𝑙 exp(𝑖𝛼ℎ𝑘𝑙) 
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The Fourier transform requires the knowledge of both parts. The amplitudes can be 
easily calculated from the experimental data, as they are proportional to the square root 
of the measured reflection intensities. However, the phase associated with each 
reflection cannot be obtained directly from the diffraction pattern. This leads to the 
phase problem, which can be solved by a number of techniques such as multiple 
isomorphous replacement, anomalous scattering and molecular replacement. These 
methods provide approximate initial phases, whereas more accurate phases are obtained 
later on during model refinement. Molecular replacement was the principle technique 
used to solve the structures mentioned in this thesis and is described below. 
2.5.7 Molecular replacement 
This method uses atomic coordinates of a previously solved, structurally similar model 
to estimate the initial phases for the unknown protein structure. The success of 
molecular replacement depends on the structural homology of the proteins, which 
usually correlates well with their sequence identity. Molecular replacement involves the 
fitting of the known model structure in the correct orientation and position in the 
experimental unit cell. It is a generally six dimensional problem, requiring three rotation 
angles to orient the molecule and three parameters describing its location in the unit 
cell. The search method can be treated as two separate 3D problems. The Patterson 
function is used to determine the relative orientation of the search molecule. It is a 
modified electron density function, where the structure factors (amplitudes and phases) 
are substituted with the intensities (amplitudes squared) and is written as 
𝑃 𝑢𝑣𝑤 = 1𝑉 |𝐹(ℎ𝑘𝑙)|!!!" cos[2𝜋(ℎ𝑢 + 𝑘𝑣 + 𝑙𝑤)] 
The Patterson function gives a map of the vectors between each pair of atoms in the 
structure and is defined by generic coordinates u, v, w as opposed to x, y, z that define 
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the unit cell. The advantage of the Patterson function is that it can be calculated directly 
using experimental data and without knowing phase angles as these are set to zero. To 
get the correct orientation of the search model in the unit cell, its Patterson map is 
calculated using the atomic coordinates and then overlaid onto the Patterson map 
derived for the unknown structure, which is calculated from the experimental 
intensities. Once the correct orientation is determined, the translation vector, positioning 
the search molecule in the cell unit with respect to the origin can also be obtained.  The 
Patterson function is able to simplify the determination of rotation matrix and 
translation vector because its interatomic vectors belong to two categories. The 
intramolecular vectors are between the atoms of the same molecule, and thereby depend 
only on the orientation of the molecule, but not on its placement within the unit cell. 
These vectors are used to derive the correct rotation matrix. On the other hand, the 
intermolecular vectors depend on both the orientation of the molecule and its location in 
the cell, so these are used to obtain the translation vector. Molecular replacement is a 
quick method to determine the initial phases, which allow structure factors to be 
calculated and the subsequent construction of the electron density map. 
2.5.8 Non-crystallographic symmetry averaging 
The initial phases and therefore maps derived by molecular replacement can contain 
large errors due to the poor quality of either diffraction data or search model. One 
technique to improve these is to use map averaging, which is applicable when multiple 
copies of a protein are present within the asymmetric unit, referred to as non-
crystallographic symmetry (NCS). In such instances the diffraction pattern and hence 
the electron density map will contain redundant information. Therefore, the electron 
density of the several almost identical molecules can be averaged. The repeating 
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features will be amplified, whereas noise and ambiguous density will be suppressed. 
This process can greatly improve the accuracy of the original phases. 
2.5.9 Model building and refinement 
Upon obtaining the first electron density map, the structure rebuilding begins. The 
model used in molecular replacement is changed appropriately to reflect the molecule 
present in the crystal. The changes to improve agreement with the electron density map 
include substitution, insertion and deletion of amino acids, as well as loop 
modifications. Following initial rebuilding, the model is refined. Refinement is an 
iterative process aiming to minimize the differences between the calculated and the 
observed structure factors. To achieve this, various parameters have to be adjusted. The 
parameters modified during model refinement include three positional variables (x, y, z) 
for each atom and the temperature factor B, where 
Bj = 8𝜋! U!! 
Uj2 is the mean square displacement of atom j and B-factor reflects atom’s mobility or 
smearing in space. The B-factor model used in refinement of protein structures is 
usually isotropic, thereby describes only the amplitude of displacement. In contrast, 
higher resolution structures in small molecule crystallography allow more complicated 
models that describe the individual anisotropic displacement of each atom. In protein 
crystallography, the number of measured data is frequently not sufficient to describe all 
parameters defining each atom. Consequently, to obtain a reliable structure, some 
parameters have to be restrained towards the ideal values. The stereochemical restraints 
are set on the distances between atoms, torsion angles and van der Waals contacts. The 
ideal values for these geometrical parameters are derived from high-resolution small 
molecule crystallography. After each round of refinement, the new phases are computed 
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from the refined model. This allows a more accurate electron density map to be 
calculated, which is inspected and changed, and then refined again to improve it further. 
The cycles of manual model corrections and automated optimisation are repeated until a 
good correlation is achieved between calculated and experimental data.         
The overall agreement is measured by crystallographic R-factor (Rwork):  
𝑅!"#$ = 𝐹obs − 𝐹cal!!" 𝐹obs!!"  
where |Fobs| and |Fcal| are the observed and calculated structure factor amplitudes. 
However, relying on Rwork value on its own can be dangerous, as it can lead to model 
over-fitting. This occurs when Rwork is reduced artificially by refining model parameters 
for which no justification is present in the experimental data. For this reason, an 
additional Rfree parameter is used. Rfree is calculated using a similar equation as Rwork, but 
with a fraction of randomly selected reflections (usually 5 %), which were kept separate 
and not included in the model refinement. Rfree provides an independent assessment of 
model correctness in the refinement process. Both Rwork and Rfree values are reduced 
over the course of refinement, with refinement considered complete when Rfree does not 
decrease further and when there are no significant peaks in a difference density map.  
2.5.10 Software for protein structure determination and analysis  
Programs from the CCP4 (Winn et al., 2011) program suite were used for data 
processing, structure determination and refinement. Diffraction data sets were indexed 
and integrated with iMOSFLM or MOSFLM (Battye et al., 2011; Leslie, 2006) and 
scaled with either SCALA or AIMLESS (Evans, 2006). Determination of structures by 
molecular replacement was done using Phaser (McCoy et al., 2007). The output models 
were manually rebuilt in Coot (Emsley et al., 2010) and refined with REFMAC5 
(Murshudov et al., 2011). The images showing protein structures were prepared with 
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PyMOL (Schrödinger). Protein sequences were aligned with ClustalW2 and these 
alignments were illustrated using ALINE (Bond and Schüttelkopf, 2009). PISA (Protein 
Interfaces, Surfaces and Assemblies; Krissinel and Henrick, 2007) was used to calculate 
surface and dimer interface areas, while DALI (Distance matrix ALIgnment; Holm, 
2010) and PDBeFold were used to perform structural alignments.  
2.6 Fragment screening techniques 
2.6.1 Differential scanning fluorescence (DSF)  
Differential scanning fluorimetry (DSF), also referred to as the thermal shift assay, is a 
technique used to study protein stability in solution. The method monitors thermally 
induced structural changes in the protein using an environmentally sensitive 
fluorescence dye, which is commonly polarity sensitive. This dye’s fluorescence 
emission is quenched in aqueous solution. However, when the protein unfolds as the 
temperature increases, the dye binds the hydrophobic regions and its fluorescence 
increases (Niesen et al., 2007). The point at which the concentrations of the folded and 
unfolded protein are equal is called the melting temperature (Tm) and is determined by a 
simple fitting procedure (Figure 2.3). This transition midpoint can be used to compare 
whether the protein is stabilized or destabilized under a certain condition relative to a 
reference. DSF is a high throughput method, which requires minimal amounts of 
sample. Its applications include the identification of stabilizing buffer conditions as well 
as ligand screening (Cummings et al., 2006).  
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Figure 2.3 Example of the thermal profile 
obtained from DSF experiment.  
The melting temperature of a protein was increased 
by 3 °C in the presence of its ligand. Figure was 
adapted from a paper (Scott et al., 2012). 
 
 
 
 
 
DSF was used to screen SENP1 and Siah1 against the Maybridge Ro3 Fragment Library 
(Maybridge). The library consists of approximately 1000 compounds with 
physicochemical properties defined by the “Rule of Three” (Congreve et al., 2003). The 
stock compounds were prepared at 100 mM concentration in 100 % DMSO. The 
SYPRO Orange dye (Life Technologies) was purchased as 5000x stock concentration 
and was diluted 1000 times in the protein solution. The protein sample was then 
dispensed into the wells of a 96 well PCR plate (Thermo Scientific), followed by the 
addition of the fragments to give the final volume of 40 µL in each well. The final 
protein concentration in the screen was 10 µM. SENP1 was screened at two 
concentrations of fragments (1 mM and 10 mM), while Siah1 was screened against the 
final fragment concentration of 1 mM. The screen was run using Mx3005p qPCR 
instrument (Stratagene). The fluorescence intensity was monitored with excitation and 
emission wavelengths of 492 nm and 610 nm, respectively. Plates were scanned from 
25 oC to 95 oC with a heating rate of 1 °C min-1. Tm values were extrapolated fitting the 
raw data to Boltzmann model using Prism (GraphPad Software). Wells containing 
protein solution and dye were used as the reference Tm. The melting curves and thermal 
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shifts were visualised using a modified Microsoft Excel spreadsheet 
(ftp://ftp.sgc.ox.ac.uk/pub/biophysics).  
2.6.2 Surface plasmon resonance (SPR) 
Surface plasmon resonance (SPR) is a method for detection and quantification of 
biomolecular interactions (Giannetti, 2011). The SPR phenomenon occurs in an 
electrically conducting metal film placed between media of different refractive index. In 
a typical sensor chip, two media materials are the glass and the sample solution, which 
are separated by a thin gold film. The polarized light is focused onto the metal surface at 
an angle of total internal reflection and the intensity of the reflected light is being 
constantly monitored (Figure 2.4). At the certain angle of incident the reflection 
intensity drops as the energy of light photons is transferred into oscillating the mobile 
electrons of a metal plate. The angle at which the intensity decreases the greatest is 
known as the SPR angle. This angle is very sensitive to the refractive index of the 
medium adjacent to a metal surface. Therefore, changes in mass on the sensor chip 
surface that result from the binding or dissociation of the molecules alter the refractive 
index and hence the SPR angle. The changes in SPR angle are detected in real time and 
are plotted as response unit (RU) against time, producing a sensorgram (Biacore Sensor 
Surface Handbook, 2008). 
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Figure 2.4 The principle of SPR.  
Polarised light shines onto the sensor chip coated with a gold layer and the reflected beam is detected. At 
a particular angle of incidence, the light photons cause the free electrons to oscillate, resulting in the dip 
in the intensity. This SPR angle depends on the mass of a bound material at the sensor chip surface. The 
interaction between immobilised molecule (the ligand; red “Y” symbols) and its binding partner (the 
analyte; yellow circles) increases the overall mass on a surface, thereby increasing the refractive index 
and will cause the SPR angle to shift from I to II. The diagram was reproduced from Delmar et al., 2004. 
  
2.6.2.1 Protein immobilisation 
All SPR studies were performed at 25 °C using Biacore instruments (GE Healthcare). A 
fragment screen was run on a Biacore 4000; with the subsequent titration experiments 
run on models 3000 and 4000. Prior to the start of each new experiment, the system was 
cleaned using Biacore maintenance kit and a fresh NTA sensor chip was inserted, which 
was preconditioned and normalised according to the instructions displayed by the 
software. Siah1 was captured on the surface of the Sensor Chip NTA (GE Healthcare) 
using the N-terminal histidine tag. The NTA sensor chip’s surface consists of a 
carboxymethylated dextran matrix with immobilised nitrilotriacetic acid (NTA), which 
allows the binding of histidine-tagged molecules through metal chelation such as Ni2+. 
In addition, Siah1 was immobilised on the same chip covalently by amine coupling. The 
surface of the NTA sensor chip also contains carboxyl groups, which are first activated 
with a mixture of carbodiimide (EDC) and N-hydroxysuccinimide (NHS) to produce 
reactive succinimide esters. The esters react spontaneously with primary amine groups, 
such as free amino groups on lysine residues, to link the protein to the dextran matrix. 
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Following immobilisation of Siah1, Tris buffer was injected to inactivate any remaining 
succinimide esters on the surface. Table 2.5 outlines the main parameters employed in 
immobilising Siah1 on the sensor chip’s surface for fragment screening. 
Sensor chip Series S Sensor Chip NTA 
Channels Fc1, Fc2, Fc3, and Fc4 
Spots 1,2,4,5 – protein; 3 – reference surface 
Flow rate  10 µL min-1 
Siah1 concentration 200 nM  
Protein buffer 50 mM HEPES pH7.5, 150 mM NaCl, 1 mM TCEP 
Immobilisation running buffer 50 mM HEPES pH7.5, 150 mM NaCl, 1 mM TCEP, 0.005 % 
Tween 20 
Injection steps Reagent Contact time 
1 500 µM NiCl2  1 min 
2 EDC/NHS 7 min 
3 Protein sample 10-15 min 
4 100 mM Tris pH 8.0 7 min 
Table 2.5 Immobilisation conditions for Siah1 
 
2.6.2.2 Fragment library screening 
The SPR screen was performed using AstraZeneca’s in-house fragment library, which 
contained 3072 compounds. The molecular weight (MW) of the fragment library ranged 
from 130 Da to 466 Da. The average MW was 228 Da, equating to 17 non-hydrogen 
(heavy) atoms. 2 µL of each fragment at 25 mM concentration in 100 % DMSO were 
dispensed into 384 well plates by the in-house Compound-Storage Unit. 98 µL of the 
sample preparation buffer were added later using the automatic dispensing robot to give 
a final concentration of 500 µM. The plates were then sealed and vortexed in a 
centrifuge to get solutions to the bottom of the wells and remove the air bubbles. The 
main solutions used to set up the fragment screen are presented in Table 2.6. 
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Running buffer 50 mM HEPES pH7.5, 150 mM NaCl, 1 mM TCEP, 0.005 % 
Tween 20, 2 % DMSO 
Sample preparation buffer 50 mM HEPES pH7.5, 150 mM NaCl, 1 mM TCEP, 0.005 % 
Tween 20 
Positive control Stock solution of 100 mM plectin peptide was diluted to 2.5 µM in 
the running buffer 
Negative control Running buffer 
Solvent correction samples Sample preparation buffer containing 1.4 %, 1.6 %, 1.8 %, 2.0 %, 
2.2 %, 2.4 %, 2.6 % and 2.8 % DMSO  
Preparation of compounds Stock solutions at 25 mM in 100 % DMSO were diluted to 500 µM 
in sample preparation buffer 
Table 2.6 Solutions used in a fragment screen of Siah1 
 
Positive and negative control samples were injected every 50 cycles to monitor protein 
activity. Solvent corrections were performed every 100 cycles to check the influence of 
DMSO. The flow rate was 30 µL min-1, with injection and wash steps set at 60 seconds 
each.     
2.6.2.3 Fragment hit characterisation     
Titration experiments were performed to confirm and characterise the hit compounds. 
Six concentration points, varying from 2 µM to 2 mM, were chosen to cover the 
expected range of fragment binding affinities. 100 mM stock solutions were prepared by 
dissolving solid compounds in 100 % DMSO. These were subsequently diluted to 2 
mM in sample preparation buffer. The 2 mM samples were then used to perform four 
fold dilutions in the running buffer in five increments, resulting in 2 mM, 500 µM, 125 
µM, 32 µM, 8 µM and 2 µM solutions. The later SPR screen of the near neighbours of 
the top five hits obtained from a fragment screen was performed at the same six 
concentrations. However, these compounds were prepared in 100 % DMSO at the 
appropriate concentrations directly by the in-house Compound Storage Unit, and the 
sample preparation buffer was then added to reach the final titration concentrations. 
Solvent correction samples, positive and negative controls were prepared and run using 
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the same method employed in the case of the fragment screen. The flow rate and 
injection time were left the same, with the wash step increased to 240 seconds. SPR data 
were analysed using Biacore 4000 Evaluation Software and Scrubber2 (BioNavis).     
2.6.3 Nuclear magnetic resonance (NMR)  
Nuclear magnetic resonance (NMR) spectroscopy is an important technique for 
structure determination and ligand screening. Detection of ligand binding can be studied 
by two main types of NMR experiment. They are known as ligand and target based 
methods depending on which part of the protein-ligand complex is being observed. 
Ligand based 1D methods detect changes in the ligand spectrum, occurring when the 
energy is transferred to the ligand from either the protein or solvent upon its binding to 
the protein (Lepre, 2011). The widely used 1D NMR techniques are saturation transfer 
difference, water ligand observed via gradient spectroscopy, and T1 and T2 relaxation 
experiments (Mayer and Meyer, 1999; Dalvit et al., 2000; Hajduk et al., 1997). The 
target based 2D methods, such as 1H-15N HSQC experiments that require 15N-labelled 
protein, are used to screen and validate compound binding simultaneously (Shuker et al, 
1996). The 15N-1H HSQC spectrum shows the peaks corresponding to each amide 
nitrogen in the protein, thereby revealing individual protein residues (except proline). 
The position of the peaks is sensitive to the chemical environment and the chemical 
shifts are observed upon ligand binding. This approach can provide direct information 
about the localisation of ligand binding, as the largest perturbations are expected to 
occur at the ligand binding site. The advantages of 1D NMR over 2D methods include 
no upper limit on MW of the proteins, no need for isotopically labelled protein and they 
require less protein (Scott et al., 2012; Hubbard, 2011; Holdgate et al., 2010). However, 
2D methods tend to be more robust with low false positive rates and can provide the 
binding site and more accurate Kd measurements.     
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The NMR experiments were performed with the help of Dr. Vajpai Navratna 
(AstraZeneca). The primary screen of SENP1 with 384 fragments from AstraZeneca’s 
in-house fragment library was performed using 1D NMR experiments. The stock 
compounds were prepared in DMSO-d6 at a 100 mM concentration. 1 µL of each 
compound in the set of six was subsequently added to 500 µL of the protein solution (20 
mM Tris-HCl pH8.0, 50 mM NaCl, 1 mM TCEP, 5 % D2O) containing SENP1 at 10 
µM concentration. Therefore, the final volume of sample in the NMR tubes was 506 µL 
and the final concentration of fragments was approximately 200 µM. The runs 
containing the mixtures of compounds in a buffer were used as a reference. The 2D 
target observed 1H-15N HSQC experiments were performed with isotopically labelled 
SENP1 and Siah1 proteins for further characterisation of individual compounds. These 
were run at a protein concentration of 100 µM and the compounds were then added in 
steps, ranging from the initial to the final concentrations of around 50 µM to 4 mM.  
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3.1 Aims 
The aims of this project were to investigate human Siah1 by producing soluble protein 
and performing a fragment-based screen against it. Further objectives were to determine 
the crystal structure of Siah1 and use X-ray crystallography to validate potential hits. 
Siah1 is a scaffolding protein, where the interface with its substrates is formed via a flat 
shallow surface, making it a difficult target for drug discovery. This study would inform 
as to whether or not a fragment-based approach can identify the ligands of Siah1 and 
which screening technique might be applicable.  
3.2 Recombinant Siah1 expression and purification 
The gene coding for Siah1 without the RING domain was obtained from a commercial 
source and was subsequently inserted into a pET15b-TEV vector for protein expression 
(see section 2.2.1). The protein was expressed in Bl21 (DE) Gold cells and purified 
using nickel affinity and gel filtration chromatography as described in sections 2.3 and 
2.4, respectively. 15N-labelled Siah1 for NMR studies was expressed in the appropriate 
minimal media and purified using a similar protocol. However, isotopically enriched 
Siah1 and Siah1 used for SPR studies were purified with the histidine tag left on by 
skipping the TEV digestion step. The protein used for DSF screening and for structural 
studies was purified without the tag. Irrespectively, Siah1 eluted from the gel filtration 
column as a symmetric peak. Siah1 with the tag removed eluted with a mass of 
approximately 39 kDa (Figure 3.1). The theoretical mass of Siah1 is 21,897 Da, which 
suggests Siah1 is a homodimer in solution. This is consistent with the earlier 
observations reporting Siah1 as a dimeric protein (Polekhina et al, 2002). The purity of 
the sample during purification was monitored by SDS-PAGE (Figure 3.1). Typical final 
yields were 10 – 15 mg L-1 of cell culture. The purified protein was kept at 4 °C for 
short-term storage and flash frozen in liquid nitrogen for long-term storage at -80 °C. 
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Figure 3.1 Size exclusion chromatography and SDS-PAGE analysis. 
The column was equilibrated using five standards labelled A to E. The red dot on the calibration curve 
marks the eluted peak. The peak corresponded to approximately 39 kDa, equivalent to a Siah1 dimer. 
SDS-PAGE analysis after each purification step is shown on the right hand side.  
 
3.3 Fragment screening 
3.3.1 DSF 
The thermal profile was measured to check that Siah1 is applicable to DSF prior to 
beginning the fragment screen. A single melting curve was observed, suggesting the 
presence of a globular domain with a melting temperature of 64.5 ºC (Figure 3.2). The 
fragment screen was performed as described in section 2.6.1. The final concentrations 
of protein and fragments were 10 µM and 1 mM, respectively. The results are presented 
in Figure 3.3. Thermal shifts larger than 2 oC were considered to be significant. This 
threshold value, corresponding to about three times the standard deviation of the 
measured melting point, was chosen based on the previous DSF studies in the 
laboratory. Two compounds produced temperature shifts above this set value. However, 
54 
 
 
Chapter 3- Results and discussion: Seven-in-absentia homolog 1  
they had untypical melting curves with decreased fluorescence levels, suggesting non-
specific binding and protein denaturation, and were not investigated further. 
Figure 3.2 The thermal profile of Siah1. 
Protein is in 50 mM Tris-HCl pH7.5, 50 
mM NaCl buffer and displays single 
melting curve with Tm of 64.5 ºC.   
 
 
 
 
 
Menadione was reported to inhibit Siah1 activity in the Meso Scale electro-
chemiluminescent assay and in in vivo experiments using 293T cells in the previous 
study (Shah et al., 2009). Its binding to Siah1 was tested using DSF at 1 mM 
concentration, but no changes in the Tm were observed. 
 
Figure 3.3 Results from the Maybridge library screen using DSF.  
Each column represents the number of compounds that produced a temperature shift within a particular 
range.  
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3.3.2 SPR 
Siah1 was immobilised on the sensor chip’s surface using the histidine tag as described 
in section 2.6.2.1. The immobilisation levels of Siah1 were approximately 3500 RU. A 
search of the literature for a potent Siah1 binder that could be used as a positive control 
revealed the plectin-195-117 peptide. It had a Kd value of around 100 nM as measured by 
SPR (House et al., 2003). This 23 residue and a shorter nine-residue peptide were 
purchased and tested (see Table 2.1 for amino acid sequences). Figure 3.4 shows the 
sensorgrams and a dose response curve for the plectin peptide injections at 10 different 
concentrations ranging from 19.5 nM and going up two fold to 10 µM. The data were 
fitted using a Langmuir binding isotherm  
𝑅!"# =  𝑅!"# × [𝐶]𝐾! + [𝐶]  
in which [C] is the concentration of injected ligand, Robs is the observed ligand binding 
and Rmax is the maximum binding capacity, when all protein binding sites are occupied. 
It is the simplest binding model and makes a number of assumptions: the ligand is 
monovalent, the protein on the surface is homogeneous and all binding events are 
independent. The Langmuir binding model yielded the Kd values of about 28 µM and 
225 nM for the shorter and a longer plectin peptide, respectively, and was applied to fit 
the data from compound titration experiments.  
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Figure 3.4 SPR data showing the binding of the positive control to Siah1.  
Sensorgrams (A) and dose-response curve (B) are presented. The plectin peptide was injected at the 
following concentrations: 19.5 nM, 39 nM, 78 nM, 156 nM, 312 nM, 625 nM, 1.25 µM, 2.5 µM, 5 µM 
and 10 µM. Siah1 immobilisation levels were 5000 RU, resulting in Rmax of 500 RU. The peptide 
saturated the protein’s surface at concentrations above 2.5 µM, thereby this concentration of the positive 
control was chosen for the screen. 
 
The plectin peptide was subsequently used as a positive control to measure the 
functional integrity of immobilised Siah1. Protein activity levels were determined with 
the assumption that plectin peptide binds Siah1 at 1:1 stoichiometry using the following 
equation 
Protein activity level  =  protein MWligand MW   ×   𝑹𝒎𝒂𝒙 (RU)immobilised protein level (RU). 
Rmax was measured experimentally to be 350 RU and using this value the initial activity 
level of immobilised Siah1 was calculated to be approximately 90 %. The plectin 
peptide was injected at even intervals during the fragment screen and revealed a gradual 
decrease in surface activity over the course of the run. Sample responses were later 
adjusted to compensate for this drop in surface activity. DMSO solvent corrections were 
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applied to eliminate the DMSO contributions to the sample responses. Fragment data 
were also referenced for blank injections and blank reference flow cell.  
The Rmax, corresponding to the upper limit of responses for 1:1 fragment protein binding 
was calculated from the rearranged protein activity equation. The Rmax of 30 RU was 
determined using the average MW of all fragments. The lower cutoff level was 
subsequently set at 10 RU. This value was derived from the Langmuir equation based 
on 500 µM fragment screening concentration and the Kd values set at 1 mM and higher. 
3072 fragments were screened in total and the screening results are presented in Figure 
3.5. The two horizontal lines show the upper and lower cutoff levels. The spots 
represent individual fragments and are coloured according to their response levels. The 
red spots belong to the fragments whose responses exceeded 1:1 stoichiometry, 
suggesting they either bind to multiple sites or aggregate non-specifically on the surface 
of the protein.  
 
Figure 3.5 A plot of the responses obtained from the fragment screen.  
Response levels for the compounds are plotted against injection cycle numbers. The upper and lower 
cutoff levels are shown by the horizontal lines. The blue spots indicate fragments whose response levels 
were below the lower cutoff of 10 RU. Fragments whose responses fell within the range of 1:1 binding 
are shown as green spots. The red spots represent fragments whose stoichiometry was above 1:1.  
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39 compounds that exhibited responses above the lower threshold were selected for 
further investigation, following the manual inspection of their sensorgrams. These were 
subsequently screened at six concentrations in the range between 2 µM and 2 mM. The 
responses and sensorgrams obtained were used to classify 39 fragments into four groups 
(Figure 3.6).     
 
Figure 3.6 Compounds exhibit different types of binding behaviour.  
These were: typical transient binding (A), promiscuous binding (B) and concentration-dependent 
aggregation (C).   
 
Five fragments exhibited typical transient binding behaviour. These compounds bound 
reversibly, eventually dissociating to baseline and either obeyed 1:1 binding model or 
reached saturation levels above Rmax, but remained below 2:1 stoichiometry. Seven 
fragments were classified as promiscuous binders. They showed nonstoichiometric 
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binding, where binding responses exceeded Rmax by more than a factor of two and some 
bound to the protein surface irreversibly. The third group contained 12 fragments that 
showed concentration-dependent aggregation. Compounds belonging to this group 
behaved well at low concentrations, where they showed no signs of promiscuous or 
nonstoichiometric binding. However, their responses became significantly 
disproportionate from the levels expected for a 1:1 binding model at higher 
concentrations. The final group included 15 compounds whose sensorgrams failed to 
show binding responses above the lower threshold level of 10 RU. 
The search of AstraZeneca’s compound library was performed to identify the 
compounds structurally similar to five fragments that showed transient binding 
behaviour. 146 near neighbour compounds were selected for the dose response 
experiments. These were performed at six concentrations as described in section 2.6.2.3. 
The data were analysed in the same way as the data from the titration experiments with 
39 fragment hits from the initial fragment screen. 21 compounds were chosen for 
further structural studies using X-ray crystallography (section 3.6). Figure 3.7 depicts 
the chemical structures and SPR data of three of those 21 fragments. The top fragments 
exhibited a Kd of around 1 mM. However, the majority of fragments failed to reach 
saturation levels at the highest screening concentration and their data were not reliable 
enough for a kinetics analysis.  
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Figure 3.7 Examples of the potential fragment hits identified.  
Sensorgram data from the titration experiments are shown on the left-hand side. Dose-response curves 
and chemical structures are presented on the right-hand side. Chemical formulae and molecular weights 
are shown next to the structures. Blue lines indicate the upper cutoff levels for 1:1 binding (Rmax). The 
compounds were classified as typical transient binders. Compound I (A) exhibited 1:1 binding behaviour. 
Compounds II (B) and III (C) had responses exceeding the Rmax expected for 1:1 interaction. 
 
3.3.3 NMR 
NMR experiments were run to test the binding of two synthetic peptides and 
menadione, which was reported to inhibit Siah1 function in the literature (Shah et al., 
2009). These were performed as described in section 2.6.3. The binding of the nine and 
23-residue peptide was observed using 1D and 2D NMR experiments, respectively. The 
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measured Kd for the nine-residue peptide was 40 µM. The Kd for the plectin peptide was 
not determined. The 1H-15N HSQC spectra of 15N-labelled Siah1 were measured prior 
and following the addition of menadione. The overlaid spectra revealed changes in peak 
position indicating binding (Figure 3.8). However, protein precipitation was observed 
during these experiments at menadione concentrations above 1 mM. Thus, NMR failed 
to conclusively determine whether the menadione interaction is specific or non-specific.  
 
Figure 3.8 Superposition of 2D 1H-15N HSQC spectra of Siah1 and Siah1-plectin peptide. 
Overlaid spectra show Siah1 (red) and Siah1-plectin peptide complex (blue) in 50 mM HEPES pH7.5, 
100 mM NaCl and 5 % D2O. 
 
3.4 Crystallisation and data collection 
The crystal structures of Siah1 in complex with the fragments identified in section 3.3.2 
were required to validate their binding. Thus, conditions were sought-after that produce 
apo-crystals of Siah1 for subsequent ligand soaking experiments as well as conditions 
promoting co-crystallisation of the protein-ligand complexes. Initial crystallisation 
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screens were performed using a sitting drop vapour diffusion method with commercially 
available formulations (see section 2.5.3). Crystallisation occurred within three days at a 
protein concentration of 10 mg mL-1 in several conditions. Two conditions were refined 
to yield diffraction quality crystals. Optimised crystals grew from equal volumes of 
protein solution (15 mg mL-1 in 15 mM Tris-HCl pH7.5, 30 mM NaCl and 10 mM 
DTT) and reservoir solution containing either 100 mM MES pH6.5, 1.5 M MgSO4 
(Figure 3.9) or 100 mM HEPES pH7.0, 1.45 M Li2SO4. Crystals had similar shape and 
size irrespective of the reservoir used. Crystals were soaked in a cryoprotectant 
containing the mother liquor solution supplemented with 20 % (v/v) glycerol before 
being cryocooled at -173 ºC. Diffraction data were collected in-house using a Rigaku 
MicroMax-007 rotating-anode X-ray generator (copper Kα, λ = 1.5418 Å) coupled to an 
R-AXIS IV++ image plate detector. The protein crystallised in space group I222 with 
unit cell lengths a = 75.14 Å, b = 104.59 Å, c = 133.16 Å (Table 3.1).         
 
Figure 3.9 Siah1 crystals.  
(A) The optimised crystals grew over three days in the reservoir condition 100 mM MES pH6.5, 1.5 M 
MgSO4. (B) The crystals diffracted in-house to 1.95 Å. 
 
3.4.1 Structure solution and refinement 
The structure was determined by molecular replacement with Phaser (McCoy et al., 
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2007) using a molecule of human SENP1 (PDB code 2a25; Santelli et al., 2005) as a 
search model. The Rwork and Rfree factors of the output solution subjected to a round of 
rigid body refinement using REFMAC5 (Murshudov et al., 2011) were 41.5 % and 
42 %, respectively. Model building was done in Coot (Emsley et al., 2010) and the 
structural refinement performed using REFMAC5. Tight local non-crystallographic 
symmetry restraints were employed in the initial rounds of refinement and TLS 
parameters (Translation/ Libration/ Screw) were applied in the later stages. 30-35 
residues at the N-terminal end and three internal regions, which were absent in the 
search model, were modelled in once the electron density was clear. The final model 
includes residues 91-282 and 95-282 of the native Siah1 sequence in chains A and B, 
respectively (Table 3.1). Chain A also contains an additional Met residue at the N-
terminus left from the histidine tag. In addition, the model contains water molecules and 
a number of different ligands (Tris, sulphate, glycerol, Cl- and Zn2+).  
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 Siah1 
 
Space group I222 
Unit cell dimensions: a, b, c (Å) 75.14, 104.59, 133.16 
Resolutiona (Å) 44.99 - 1.95 (2.06 - 1.95) 
No. of reflections 141688 (11394) 
Unique reflections 38340 (5357) 
Completeness (%) 99.3 (96.0) 
Multiplicity 3.7 (2.1) 
<I/σI> 19.3 (4.5) 
Wilson B (Å2) 29.2 
Residues 
 
 
 
 
Chain A 91-282 
Chain B 95-282 
Water / Cl- / sulphate / Tris / glycerol / Zn2+ 218 / 4 / 3 / 2 / 3 / 4  
Rmergeb (%) 3.7 (17.8) 
Rworkc, Rfreed (%) 19.8 / 23.9 
Mean B-factors (Å2) 
 
 
Protein  17.7 
Ligands and waters 29.4 
Ramachandran plote (%) 
 
 
 
 
 
 
Most favoured  97.4 
Additional allowed  2.3 
Outliers  0.3 
R.m.s.d. on ideal valuesf  
Bond length (Å) / bond angles (º) 0.01 / 1.30 
Table 3.1 Crystallographic statistics of Siah1. 
a. Values in parentheses refer to the highest resolution shell. b. Rmerge = ∑hkl∑i|Ii(hkl) - <I(hkl)>|/ ∑hkl∑i 
Ii(hkl); where Ii(hkl) is the intensity of the ith measurement of reflection hkl and <I(hkl)> is the mean 
value of Ii(hkl) for all i measurements. c. Rwork = ∑hkl||Fo|-|Fc||/∑|Fo|, where Fo is the observed structure 
factor and Fc is the calculated structure factor. d. Rfree is the same as Rwork except calculated with a subset, 
5 %, of data that are excluded from refinement calculations. e. (Chen et al., 2010). f. (Engh and Huber, 
1991).  
 
3.5 The Siah1 structure 
3.5.1 Structure quality 
The structure was determined at 1.95 Å resolution with Rwork and Rfree values of 19.8% 
and 23.9%, respectively. The asymmetric unit consists of two polypeptide chains with 
the solvent content of 59 % and Vm (Matthews, 1968) of 2.99 Å3 Da-1. The polypeptides 
are arranged as a dimer consistent with the dimer observation on the size exclusion 
column and in other published structures of Siah1 (House et al., 2003; Polekhina et al., 
2002; Santelli et al., 2005). Continuous, well-defined electron density is observed for 
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most of the structure; apart from a few residues at the N-terminus of Chain B. 
Ramachandran analysis reveals that 99.7 % of the amino acids are located in the 
allowed region. A comparison of the determined Siah1 structure (subunit A) and that of 
PDB entry 2a25 gives an rmsd of 0.61 Å for 140 Cα atoms.  
3.5.2 Overall structure 
Siah1 is a dimeric protein, which forms a Z-shaped structure (Figure 3.10). Each 
monomer contains two zinc finger domains and a C-terminal substrate binding domain 
(SBD), which forms the dimerization interface with an equivalent domain of the second 
subunit. Superposition of two full-length monomers gives a high rmsd value of 5.36 Å 
for 181 Cα atoms. This is due to the shift in the position of the N-terminal zinc finger 
domains relative to each other and is likely imposed by the crystal packing. The result is 
that the Zn2+ ion in this domain is displaced by about 14.5 Å when the monomers are 
overlaid. Superposition of the monomers without their N-terminal zinc fingers gives a 
lower rmsd of 0.886 Å for 150 Cα atoms.  
Figure 3.10 Overall structure of Siah1.  
The homodimer is shown as a cartoon. The zinc 
fingers are coloured red and blue, the substrate 
binding domain (SBD) of monomer A and B are 
coloured green and orange, respectively. The N- and 
C- termini are labelled accordingly. The Zn2+ ions 
are shown as grey spheres. 
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The SBD forms two antiparallel β-sheets of four strands each placed on top of one 
another (Figure 3.11). The first contains strands β2, β3, β4 and β7, while the second is 
made of strands β1, β8, β5 and β6. A further strand β0 is situated parallel to β2, 
connecting the SBD with an adjacent zinc finger. In addition, the SBD contains three 
short α-helices (α1-α3) that link β4 with β5, β6 with β7 and β7 with β8.        
Figure 3.11 Structure of the 
Siah1 monomer. 
Ribbon diagram is showing the 
SBD and two zinc finger 
domains. The α-helices and β-
strands are coloured purple and 
orange, respectively. The N- 
and C-terminal positions are 
labelled, as are the α-helices 
and β-strands. The Zn2+ ions 
are shown as grey spheres.  
 
  
 
 
The total surface area of a monomer is about 10800 Å2 of which 1100 Å2 are buried 
upon dimer formation. Therefore, approximately 10 % of the surface area of each 
monomer is involved in dimerisation. The Siah1 homodimer is held together by a 
network of hydrogen bonds, salt-bridge interactions and van der Waals forces. The 
majority of these intermolecular contacts occur between the residues found on strands 
β6 of each monomer. For example, Arg232 and Arg233 on β6 of one subunit make salt-
bridge interactions to Asp255 and Glu237 of the partner subunit (data not shown). The 
equivalent arginine residues in the partner subunit make similar contacts to the residues 
in the first subunit; thereby eight salt-bridges are formed in total. A further six hydrogen 
bonds are formed between the main chains of these two antiparallel β6 strands. In 
addition, the interactions between residues at the dimer interface are mediated by a 
number of water molecules. This extensive network of different intermolecular 
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interactions suggests a tight association of the two monomers. 
3.6 Crystallisation screening 
Crystallisation was performed with compounds that exhibited binding by SPR to 
validate their interaction and to obtain information about the binding sites (see section 
3.3.2). In total, five fragments identified in the initial fragment screen and 21 near-
neighbours were used in co-crystallisation and crystal soaking experiments. Compounds 
were used in co-crystallisation at 5 mM and 10 mM concentrations, with 5 % and 10 % 
DMSO, respectively. Over ten X-ray data sets were collected and analysed, but 
compounds could not be seen in the electron density structure. In crystal soaking 
experiments, the apo Siah1 crystals were transferred into the solutions containing 
individual compounds at 20 mM concentration (20 % DMSO) before being tested. The 
majority of these crystals formed cracks and diffracted below 4.0 Å, which is likely due 
to the high concentration of DMSO. However, two data sets were collected, but upon 
structure determination the electron density map did not show the presence of the 
compounds. Therefore, none of the compounds identified by SPR could be validated as 
true hits. In addition, crystallisation was performed with the inhibitory plectin peptide at 
1-10 mM concentrations. No crystals were obtained, suggesting peptide binding 
disrupts the crystallisation interface under these conditions.     
3.7 Comparison of fragment screening methods 
DSF was not able to generate any potential hits for Siah1 in this study. The technique 
does not appear to be sensitive enough to detect the weak binding affinities, which are 
usually associated with fragments. Similar results have been obtained from fragment 
screening studies with other protein targets in the laboratory (data not shown); thereby 
providing further support for this observation. The exception was observed for 
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Pseudomonas aeruginosa penicillin binding protein 3, with thermal shifts of over 15 ºC 
and 5 ºC in the presence of known antibiotics and a number of fragment hits, 
respectively (Sainsbury et al., 2011). External studies reported that the hit rate obtained 
by DSF is generally a number of times lower than with NMR or SPR (Hubbard and 
Murray, 2011). Together these studies show that DSF is still applicable for certain 
protein targets, and while it is unable to reliably identify weak binders, it can be used 
for the identification of high affinity compounds. DSF is one of the quickest and 
cheapest methods for compound screening, not requiring protein labelling or prior 
knowledge of its function, and should still be considered as a preliminary screening 
method. 
The initial SPR screen identified 39 hits for Siah1, suggesting the technique is more 
applicable for fragment screening. The screen was performed at 500 µM, which was 
higher than the usual fragment concentration used in the SPR screen for targets like 
protein kinases. The fragment concentration chosen represented a compromise between 
the lower hit rate observed for protein-protein interaction targets and increased 
nonspecific fragment interactions seen at high screening concentrations (Hämäläinen et 
al., 2008). Although the screen generated 39 hits, the subsequent titration experiments 
showed that some of them were false positives from non-specific binders and 
aggregates. The false positives could have been rapidly identified by immobilising a 
Siah1 unrelated protein on one of the spots of the sensor chip to be used as a negative 
control during the screen. SPR is similar to DSF in that it allows a high throughput 
format sufficient for screening libraries containing thousands of fragments within days 
and it requires even smaller quantities of protein. However, sufficient levels of the 
protein should be immobilised to achieve a high signal to noise ratio to reliably detect 
the binding of low MW fragments. SPR is also highly sensitive and slight variations in 
buffer composition could interfere significantly with the data interpretation. Unlike 
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DSF, SPR can provide information on affinity and kinetics, which are determined from 
the time dependent fragment association-dissociation response. Studies indicate that 
SPR is able to detect the binding of fragments in the affinity range of 0.1-1000 µM 
(Hubbard and Murray, 2011). The detection of lower affinities is limited predominantly 
by aqueous solubility of the fragments being tested. In this study, the fragment hits were 
characterised at the highest concentration of 2 mM. This limited the reliable 
determination of their affinities to 1 mM. Most of the identified compounds had a lower 
Kd as they failed to reach protein saturation at 2 mM.  
The Maybridge Ro3 library (Maybridge) was screened with DSF, while the SPR screen 
was performed using an SPR tailored library (AstraZeneca) assembled from the in-
house compounds and from vendor catalogues. Both libraries are intended for screening 
a diverse range of targets, but only the Maybridge library complied with the rule of 
three (Congreve et al., 2003; see section 1.3.1). The size of its fragments varied between 
93-298 Da, with an average of 178 Da (www.maybridge.com). In comparison, the SPR 
library contained fragments from 130 Da to 466 Da, with a mean of 228 Da. Neither 
library was screened with the second technique; therefore the direct comparison of the 
two cannot be made. However, it is likely that the hit rate with the SPR when screening 
Maybridge library would have been lower. The technique is not sensitive enough to 
robustly detect the binding of the fragments found at the lower end of MW in the 
Maybridge library; thereby the response levels for the fragments of less than 100 Da 
would be too low to fit the data accurately.    
3.8 Discussion 
Ubiquitination is a post-translational modification controlling many cellular processes, 
including the regulation of protein degradation together with 26S proteasome (Krämer 
et al., 2013). In this modification, ubiquitin is attached to the target protein, with the 
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process specificity defined by the E3 ubiquitin ligases such as Siah1. Siah1 functions in 
Ras, DNA-damage, and hypoxia signalling pathways (House et al., 2009). Studies 
showed its inhibition impairs tumour growth and metastasis, making Siah1 an attractive 
therapeutic target in cancer (Wong and Möller, 2013). 
This work presents the results obtained from fragment screening experiments, which 
employed two different approaches. The first screen was run with DSF and did not 
identify any potential hits for Siah1. This and other experiences of screening with DSF, 
suggest it is not suitable as a frontline hit generation method, although it can still be 
useful as a preliminary screen for some targets. The initial SPR screen identified 39 hits 
out of 3072 fragments tested, thereby giving the hit rate of 1.3 %. However, more than 
half of those were later confirmed to be false positives. Thus, the final hit rate is close to 
0.5 %, which was a value reported by Vernalis in its screens of about 1200 fragments 
against other protein-protein interaction targets (Roughley and Hubbard, 2011). The 
results demonstrate that SPR is sensitive enough technique for identifying the weak 
binding fragments for protein-protein interaction targets, supporting previous 
observations (Nordström et al., 2008; Hämäläinen et al., 2008).      
Co-crystallisation and crystal soaking experiments were performed in an attempt to 
validate SPR hits as true binders and determine their binding mode. Thus far, the data 
sets collected did not show the presence of ligands. Alternative soaking methods could 
be tried, such as transferring the apo-crystals gradually to a series of fragment solutions 
of increasing concentration, as well as extending the soaking period. Other biophysical 
methods such as isothermal titration calorimetry (ITC) and NMR could be explored to 
verify the hits. ITC works by measuring the heat released upon the interaction during a 
series of titrations of ligand into a protein solution and yields full thermodynamic 
parameters like enthalpy and entropy (Scott et al., 2012). Two disadvantages of ITC are 
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that it requires large quantities of protein and the ligands tested need to be very soluble. 
Ligand-observed and protein-observed NMR can be used to measure affinity, with the 
later also providing information about the binding site. The drawback is the need for 
high amounts of isotopically labelled protein. Biochemical assays can often be used to 
validate hits, but no straightforward assay is available for Siah1.     
The plectin peptide was shown to bind Siah1 with a Kd of around 100 nM and to inhibit 
its activity (House et al., 2003). The same peptide was tested in this study to be used as 
a positive control in an SPR screen. A Kd of approximately 225 nM was determined, 
which is not far off the reported value. The initial value was measured using biosensor-
based method with the peptide immobilised on the sensor surface, while SPR 
experiments performed here used immobilised protein and the peptide was injected in 
aqueous solution. In addition, two experiments were run under different buffer 
conditions, which might explain the slight variations in the determined Kd values. The 
binding of plectin peptide was also detected with protein-observed NMR (data not 
shown). The interaction site of such peptides containing a conserved VxP motif in their 
sequences with Siah1 is known (Figure 1.5; House et al., 2006). Therefore, SPR 
competition assays can be performed in future to test indirectly whether the compounds 
identified in the fragment screen bind at the same site as the plectin peptide.    
The apo-structure of Siah1 was determined at an improved resolution of 1.95 Å (see 
section 3.5). The structure contains the residues in three loop regions that were missing 
in a search model as well as the whole zinc finger motif adjacent to the RING domain. 
This more accurate model of Siah1 may aid future structural experiments investigating 
Siah1-ligand complexes. 
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4.1 Aims 
The objectives of this project were to probe the druggability of the catalytic domain of 
human cysteine protease SENP1 using a fragment-based approach. This study would 
inform whether fragment screening is applicable for generating the starting chemical 
entities for further drug development process for such targets. In addition, the crystal 
structure of SENP1 was sought in order to follow up the hits obtained from a fragment 
screen with structural studies.  
4.2 Recombinant SENP1 expression and purification 
The pHISTEV30a plasmid containing the gene encoding the catalytic domain of SENP1 
was a kind gift of Ron Hay (University of Dundee). The protein was expressed and 
purified as described in sections 2.2 and 2.4. 15N-labelled SENP1 for NMR studies was 
expressed in the minimal media and purified using the same protocol. SENP1 eluted 
from the gel filtration column as a single peak with a mass of around 21 kDa. A 
monomer has the theoretical mass of 28,042 Da (Figure 4.1). The purity of the final 
sample was estimated at >95 % as checked by SDS-PAGE (Figure 4.1). A final yield 
was approximately 30 mg L-1 of cell culture. The purified protein was stored at 4 °C and 
flash frozen for storage at -80 °C until further use.  
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Figure 4.1 Size exclusion chromatography and SDS-PAGE analysis.  
The calibration curve was plotted using five standards labelled A to E. The eluted peak is represented by a 
red dot on a calibration curve. The peak corresponded to approximately 21 kDa; suggesting SENP1 is a 
monomeric protein. SDS-PAGE gel, showing the protein sample after each purification step, is depicted 
on the left.  
 
4.3 Fragment screening 
4.3.1 DSF 
A DSF run of the protein in a buffer was performed first to establish if SENP1 is 
amenable to this technique. The thermal profile of SENP1 showed a single melting 
curve, indicative of a folded protein. The melting temperature was 44.8 ºC in 20 mM 
Tris-HCl pH8.0, 50 mM NaCl buffer used in a fragment screen (Figure 4.2).  
Figure 4.2 The thermal profile of SENP1. 
Protein displays a single melting curve with 
Tm of 44.8 ºC.   
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The fragment screen was performed as outlined in section 2.6.1. The compounds were 
initially screened at the final concentration of 1 mM. Compounds that stabilised the 
protein by over 2 oC were classified as hits. This arbitrary cut-off value was set based on 
the previous experience of compound screening in the laboratory. None of the 
fragments produced temperature shifts above the threshold, with the best compounds 
stabilizing SENP1 by 1 oC (Figure 4.3). The original screen was repeated at the 
fragment concentration of 10 mM. This meant screening SENP1 at a higher DMSO 
concentration because the stock compounds were prepared in 100 % DMSO. The effect 
of DMSO on SENP1 had to be tested first as DMSO generally destabilises the protein. 
SENP1 was screened at 10 different DMSO concentrations ranging from 2.5 % to 25 % 
(Figure 4.3). The results showed SENP1 was still stable at the DMSO concentration of 
20 %, thereby allowing the fragment library to be screened at 10 mM concentration. The 
results are shown in Figure 4.4. 27 compounds had temperature shifts above the 2 oC 
mark. These were the same compounds that gave the biggest temperature shifts in the 
initial 1mM screen; thereby there was a good correlation between the temperature shifts 
observed and the compound concentration used. However, the requirement to use 10 
mM concentration, suggest the compounds have low affinity for SENP1 and they were 
excluded from further characterisation.  
 
Figure 4.3 The effects of DMSO on SENP1 stability.  
(A) The thermal profiles of SENP1 at different DMSO concentrations. (B) The melting temperatures of 
the SENP1 unfolding transition decreased with increased DMSO concentration. Values shown represent 
the mean Tm measured in quadruplicate ± SD. 
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Figure 4.4 Results from the Maybridge library screen using DSF.  
Fragments were screened at 1 mM (blue) and 10 mM (red) concentrations. Each column represents the 
number of compounds that produced a temperature shift within a particular range. 
 
4.3.2 NMR 
When screening compound libraries using 1D NMR, it is preferable to have a tool 
compound, which is known to bind the target as this greatly speeds up the interpretation 
of the results. For this purpose, a short synthetic peptide corresponding to the last four 
C-terminal residues of SUMO (Gln-Thr-Gly-Gly) was purchased from GenScript and 
tested for SENP1 binding. In addition, the binding of benzbromarone, which was 
reported to inhibit SENP1 in a fluorescence resonance energy transfer based assay 
(Martin, 2008), and its three analogues was tested. 1D NMR methods could not detect 
the peptide binding and the binding of benzbromarone analogues was weak with Kd 
above 1 mM. Due to the absence of a tool control, the screen of 384 compounds from a 
library of 1100 fragments was initiated without a positive control as described in section 
2.6.3. Kd values for the top 11 fragments from this screen were estimated to be 10 mM. 
The fragment screen was subsequently terminated due to the absence of a tool 
compound, which could be used in validation of potential hits.  
 
 
 
 
Chapter 4- Results and discussion: Sentrin specific protease 1  
77 
4.4 Crystallisation and data collection 
Initial crystallisation screens were set up as sitting drop vapour diffusion experiments in 
a 96-well plate format (see section 2.5.3). Crystals grew at a protein concentration of 10 
mg mL-1 and in the reservoir formulation 100 mM MES pH6.5, 1.8 M (NH4)2SO4 and 
10 mM CoCl2. This was further refined using hanging drop vapour diffusion method in 
24 well plates. Diffraction quality crystals appeared after two days from equal volumes 
of reservoir solution (1.8 M (NH4)2SO4, 50 mM CoCl2 and 100 mM MES pH 6.5) and 
protein solution (20 mg mL-1 in 20 mM Tris-HCl pH 8.0, and 50 mM NaCl; Figure 
4.5). Crystals were cryo-protected in reservoir buffer containing 20% glycerol. Crystals 
were initially characterised in-house using a Rigaku MicroMax-007 rotating-anode X-
ray generator coupled to an R-AXIS IV++ image plate detector. Diffraction data were 
then collected at the European Synchrotron Radiation Facility beamline ID29 (λ = 0.977 
Å). The data were indexed with MOSFLM (Leslie, 2006) and scaled using SCALA 
(Evans, 2006) from the CCP4 program suite (Winn et al., 2011).  
 
Figure 4.5 SENP1 crystals.  
(A) The optimised crystals grew after two days. (B) The crystals diffracted at the ESRF synchrotron to 
2.40 Å. 
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4.4.1 Structure solution and refinement 
The structure was solved by molecular replacement with Phaser (McCoy et al., 2007) 
using the coordinates of a monomer (chain A) of human SENP1 (PDB code 2yic; Shen 
et al., 2006) as a search model. The model was manipulated using Coot (Emsley et al., 
2010) and refinement carried out using REFMAC5 (Murshudov et al., 2011). Strict non-
crystallographic symmetry restraints were applied in the early stages of the refinement. 
Water and glycerol molecules were included in the model and a positive peak (>10σ) in 
the Fo-Fc difference map was assigned as a Co2+ ion. The refinement continued until no 
significant changes in Rwork and Rfree were observed and when inspection of the 
difference density map suggested that no further corrections or additions were required. 
The stereochemistry of the structure was checked using MolProbity (Chen et al., 2010). 
Data collection and structure refinement statistics are shown in Table 1.  
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 SENP1 
Space group P3121 
Unit cell dimensions: a, b, c (Å) 71.17, 71.17, 199.99 
Resolutiona (Å) 45 - 2.40 (2.53 - 2.40) 
No. of reflections 120621 (17892) 
Unique reflections 23808 (3415) 
Completeness (%) 99.8 (100.0) 
Multiplicity 5.1 (5.2) 
<I/σI> 8.5 (2.5) 
Wilson B (Å2) 59.507 
Residues  
Chain A 418-644 
Chain B 419-644 
Water / glycerol / Co2+ 70 / 6 / 1 
Rmergeb (%) 9.0 (42.8) 
Rworkc, Rfreed (%) 23.1 / 31.3 
Mean B-factors (Å2) 
 
 
Protein 59.8 
Ligands and waters 
 
 
 
36.4 
Ramachandran plote (%) 
 
 
Most favoured  91.6 
Additional allowed 8.0 
Outliers 0.4 
R.m.s.d. on ideal valuesf  
Bond lengths (Å) / angles (º) 0.02 / 1.62 
Table 4.1 Crystallographic statistics of SENP1. 
a. Values in parentheses refer to the highest resolution shell. b. Rmerge = ∑hkl∑i|Ii(hkl) - <I(hkl)>|/ ∑hkl∑i 
Ii(hkl); where Ii(hkl) is the intensity of the ith measurement of reflection hkl and <I(hkl)> is the mean 
value of Ii(hkl) for all i measurements. c. Rwork = ∑hkl||Fo|-|Fc||/∑|Fo|, where Fo is the observed structure 
factor and Fc is the calculated structure factor. d. Rfree is the same as Rwork except calculated with a subset, 
5 %, of data that are excluded from refinement calculations. e. (Chen et al., 2010). f. (Engh and Huber, 
1991).  
 
4.5 The SENP1 structure 
4.5.1 Structure quality  
The crystal structure of SENP1 was determined at 2.4 Å resolution with Rwork and Rfree 
values of 23.1% and 31.3%, respectively. The discrepancy of 8.2 % might be due to the 
fact that optimum restraints were not selected during refinement. Thus, it might be 
useful to test different weighting schemes, like B-factor restraints, during refinement. 
The asymmetric unit contains two polypeptides, referred to as A and B, with an 
estimated solvent content of 53 % and a Vm (Matthews, 1968) of 2.61 Å3 Da-1. The two 
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subunits located within the asymmetric unit superimpose closely with an rmsd of 0.72 Å 
for 215 Cα atoms as calculated using LSQKAB (Kabsch, 1976). In addition, the 
asymmetric unit consists of 70 waters, six glycerol molecules and one Co2+ ion, 
contributing to intermolecular interactions relevant to crystallisation of the enzyme. The 
ion is tetrahedrally coordinated by Glu430 and His640 from one molecule and the 
corresponding residues from a symmetry related molecule (Figure 4.6). A 
Ramachandran plot reveals that 99.6 % of residues are found in the allowed region. 
Most of the amino acids have a well-defined electron density, apart from the side chains 
of a few lysine residues. These atoms were included in the model, but their occupancy 
was set at zero. There are no major conformational differences between human SENP1 
structure presented here and that of PDB entry 2iyc, with an rmsd of 0.43 Å for 222 Cα 
atoms when subunits A are superimposed. However, the Co2+ ion was inadvertently 
omitted in the earlier structure of this enzyme, which was crystallised in similar 
conditions containing CoCl2. The presence of the Co2+ ion was confirmed by re-refining 
entry 2iyc (data not shown).   
Figure 4.6 The Fo-Fc omit difference density 
for Co2+.  
Fo are observed, Fc the calculated structure 
factors. The map is contoured at 5σ (cyan 
chicken wire). Glu430 and His640 from two 
asymmetric units are represented as a ball-and-
stick model. Carbon positions are coloured 
grey for molecule B and black for the 
symmetry related molecule A. Oxygen and 
nitrogen positions are coloured red and blue, 
respectively; the purple sphere represents Co2+.   
 
   
 
 
4.5.2 Overall structure 
SENP1 has an overall protein fold that places it within the cysteine protease 
superfamily. The structure of the catalytic domain of SENP1 can be subdivided into two 
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subdomains. The N-terminal segment is formed by two antiparallel β-strands (β1 and 
β2) and five α-helices (α1, α2, α3, α7 and α8) (Figure 4.7). The C-terminal subdomain 
consists of a five stranded mixed β-sheet (β3-β7), where the middle strand β5 is 
antiparallel to the other four, and this sheet is surrounded by three α-helices (α4-α6). 
The SENP1 active site resembles the active sites of other cysteine proteases like yeast 
Ulp1 and human SENP2, in that it contains a conserved catalytic triad of cysteine, 
histidine and aspartate (Mossessova and Lima, 2000; Reverter and Lima, 2004; Li and 
Hochstrasser, 1999). In SENP1, the nucleophilic Cys603 is coordinated by the general 
base His533, which is in turn stabilised by Asp550. The Cys603 is located at the N-
terminus of the central helix α7, while His533 and Asp550 are situated at the front of β5 
and at the end of β6, respectively (Figure 4.7). The N- and C-terminal ends are located 
close together, but far away from the active site.  
Figure 4.7 The structure of SENP1.  
A ribbon diagram showing α-helices and 
β-strands coloured purple and orange, 
respectively. The N- and C-terminal 
positions are labelled, as are the α-helices 
and β-strands. The catalytic site of SENP1 
is enlarged. The conserved catalytic triad 
of CYS603, HIS533 and ASP550 making 
up the active site are displayed as ball-and-
stick models. Atomic positions are 
coloured: C (grey), O (red), N (blue) and S 
(orange). 
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4.6 Discussion 
The conjugation of SUMO onto target proteins is a reversible post-translational 
modification that regulates many processes including gene expression, cell cycle and 
stress responses (Cheng et al., 2006). SENP1 is a cysteine protease that catalyzes two 
essential reactions in the SUMO pathway (Yeh, 2009). It processes SUMO precursors 
to their mature form as well as deconjugates SUMO from the target proteins. Over-
expression of SENP1 mRNA and protein level is observed in over half of the 
prostatectomy cases with high-grade prostatic intraepithelial neoplasia and in prostate 
cancer cells (Cheng et al., 2006; Li et al., 2012). The effect of its up-regulation on 
progression of prostate cancer has been confirmed in the transgenic mice (Chen et al., 
2012). Therefore, SENP1 could be a promising therapeutic target for prostate cancer. 
In this study, the fragment screen was performed with SENP1 using DSF and ligand-
observed 1D NMR techniques. A commercial library of approximately 1000 fragments 
was screened with DSF at 1 mM concentration, but the screen did not identify any hits. 
The screening concentration was subsequently increased to 10 mM, and this resulted in 
27 fragments exhibiting thermal shifts above a set threshold temperature of 2 oC. 
However, the protein stabilizing effects at such high compound concentrations were still 
considered to be insignificant and therefore their characterisation was not pursued 
further. Together with results observed for Siah1 (see section 3.3.1), these DSF data 
show that the technique is not amenable for screening fragments against such protein 
targets. DSF is not sensitive enough to reliably detect the binding of compounds with Kd 
above 1 mM (Hubbard and Murray, 2011). 
SENP1 was also screened with 384 compounds from an in-house library of 1100 
fragments (AstraZeneca) using ligand-observed NMR method. The library was 
specifically tailored for NMR screening and contained fragments of lower MW 
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compared to an SPR library used in the Siah1 screen. The NMR method is able to detect 
compound binding with affinities as low as 10 mM and has been successfully utilised 
for fragment screening of many protein targets (Brough et al., 2009; Chen and Hubbard, 
2009). It is a relatively quick method, where fragments can be screened simultaneously 
in cocktails of 6-12 to achieve a higher throughput. In addition, information about the 
binding mode and fragment affinity can be obtained in cases where the site-specific 
inhibitor of the target protein is available. However, no reversible inhibitors of SENP1 
are currently available commercially and no binding was observed with the four-residue 
peptide containing the C-terminal sequence of SUMO1. Thus, the NMR screen was 
performed without a positive control and the precise Kd values for the top fragments 
could not be measured, but were estimated to be in the millimolar range. The failure to 
identify any hits with DSF and NMR screens support the earlier notion that SENP1 is a 
challenging target for high-throughput and fragment screening. Future experiments 
might concentrate on a different set of fragments and other biophysical methods like 
SPR, which identified fragment hits for Siah1. For example, the fragment library could 
be modified to include chemical moieties resembling amino acids as many SENP1 
inhibitors identified using in silico screening methods contain peptidomimetic scaffolds 
(Madu et al., 2013; Chen et al., 2012). Any future derived hits could be validated with 
fluorescence resonance energy transfer activity assay, which is well established for 
catalytic characterisation of SENPs (Shen et al., 2006). 
In addition, the apo-structure of SENP1 was solved to 2.4 Å. The structure had a similar 
fold to previously characterised SENP1 proteins. However, a new feature was identified 
in the asymmetric unit. A Co2+ ion was assigned, which contributed to intermolecular 
contacts forming the crystal lattice.  
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5.1 Background 
Siah1 ubiquitinating activity regulates over 30 proteins (Table 1.1) by targeting them 
for proteasomal degradation (see section 1.1.4). Siah1 acts either alone or as part of a 
multi-protein complex that is similar to APC and Skp1/Cul1/F-box protein ligases 
(Santelli et al., 2005). Complex assembly is thought to help recruit Siah1 substrates. In 
addition, a number of proteins interact with Siah1 to either block its activity or to 
stabilise Siah1 by inhibiting its auto-ubiquitination and degradation (Qi et al., 2013).  
5.1.1 Siah1 substrates 
Four Siah1 substrates were investigated. They were CtBP-interacting protein (CtIP), 
tribbles homolog 3 (TRB3), kinesin like DNA binding protein (Kid), and prolyl 
hydroxylase 3 (PHD3). These particular proteins were chosen based on the available 
information supporting their interaction with Siah1 and the results of bioinformatic 
analysis. CtIP is a transcriptional co-repressor that regulates cell cycle progression and 
associates with BRCA1 to mediate DNA double stranded break repair (Wang et al., 
2012). CtIP was shown to interact with Siah1 both in vitro and in vivo (Germani et al., 
2003). TRB3 is a presudokinase, acting as a scaffolding protein in insulin signalling and 
bone morphogenetic protein signalling pathways (Yokoyama and Nakamura, 2011). Its 
binding to Siah1 was identified using the yeast two-hybrid system and validated by co-
immunoprecipitation assays (Zhou et al., 2008). Kid is implicated in the normal 
progression of mitosis and was observed to bind Siah1 in a yeast two-hybrid screen 
(Germani et al., 2000). PHD3 is involved in a cellular response to hypoxia, where it can 
catalyse the hydroxylation of HIF1α, leading to its degradation. PHD3 binding to Siah 
proteins was first identified by mass spectrometry analysis, and was shown to result in 
PHD3 turnover under hypoxic conditions (Nakayama et al., 2004). These proteins were 
suggested to interact with the SBD of Siah1 involving a conserved Val-x-Pro (VxP) 
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motif in their sequences, as was shown to be the case for Siah-interacting protein (SIP; 
House et al., 2006). However, with some proteins containing more than one VxP 
sequence the exact interaction sites and mode of action are not known.       
5.1.2 Siah1 binding protein: SIP 
SIP, also known as calcyclin binding protein, is a 228 residue (about 30 kDa) protein 
normally found in the cytoplasm, but which translocates to the nucleus upon increase in 
intracellular Ca2+ levels (Wu et al., 2003). SIP is an adaptor protein that mediates its 
function through protein-protein interactions; with roles in ubiquitination, proliferation, 
cytoskeletal rearrangement and regulation of transcription (Schneider and Filipek, 
2011). SIP was identified to bind Siah1 as part of a multi-protein complex that also 
includes Skp1 and Ebi to regulate β-catenin levels (Matsuzawa and Reed, 2001). The 
interaction was subsequently confirmed by a number of biophysical studies (Santelli et 
al., 2005; Bhattacharya et al., 2005). Sequence analysis revealed SIP contains three 
distinct regions (Bhattacharya et al., 2005). The N-terminal part forms a helical hairpin 
domain involved in homodimerisation, followed by an unstructured sequence involved 
in binding Siah1. The central part folds into a seven stranded mixed β-sheet, important 
for binding Skp1. Finally, the disordered C-terminal segment is involved in binding 
calcyclin (Schneider and Filipek, 2011). The ligand-observed NMR studies using a 
shorter 80 residue isoform of SIP (SIP-S), containing identical 72 amino acids at the N-
terminus to the full length SIP, mapped the Siah1 interaction sequence to 
60PAAVVAP66 (Santelli et al., 2005). The Kd of SIP-S for Siah1 was measured by ITC 
and NMR as 10 ± 5 µM. The same group also determined the structure of Siah1 in 
complex with a 13 residue peptide of SIP-S, thereby revealing the binding site on Siah1 
(Figure 1.5). In this structure, the 60PAAVVAP66 motif forms a β-strand that lies 
parallel to the β-sheet of SBD of Siah1. The conserved valine in a VxP motif packs 
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against Phe165 and Val179, while the conserved proline stacks against the side chain of 
Trp178. Although this study confirmed SIP-Siah1 complex formation, it is not clear 
whether other parts outside the N-terminal region of SIP also contribute to the binding. 
Thus, further studies are needed using longer SIP constructs.                   
5.1.3 Siah1 binding protein: PEG3 
Paternally expressed gene 3 protein (PEG3) is a large multi-functional protein of nearly 
1600 amino acids (about 165 kDa). Its sequence contains twelve Cys2-His2 type zinc 
finger motifs, extended segments of predicted disorder and the N-terminal SCAN 
domain, named after the first letters of four founding members of the family (SRE-ZBP, 
Ctfin51, AW-1 (ZNF174), and Number 18) (Williams et al., 1995). PEG3 has 
predominantly nuclear localisation and is able to bind DNA in a sequence specific 
manner, suggesting it can act as a transcription factor (Relaix et al., 1996; Thiaville et 
al., 2013). In addition, PEG3 is known to interact with proteins in the cytoplasm to 
regulate tumour necrosis factor and Wnt (the name is a combination of homologous 
genes Wg (wingless) and Int) signal transduction pathways (Relaix et al., 1998; Jiang et 
al., 2010). The initial binding of PEG3 to a Siah2 construct missing the RING domain 
was detected in a yeast two-hybrid screen (Relaix et al., 2000). The same study reported 
the interaction of a mouse PEG3 with both Siah proteins by immunoprecipitation, while 
the later experiments using deletion generated constructs of human PEG3 revealed that 
the N-terminus including the SCAN domain (residues 1-268) were required for binding 
the full-length Siah1 (Jiang et al., 2010). Interestingly, the SCAN domain of PEG3 
(PEG3-SCAN) contains the amino acid sequence of 58VGP60, which could be a 
consensus Siah1 binding motif, but studies are required to confirm this hypothesis. 
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5.2 Aims   
The aims of this project were to validate the binding of the aforementioned proteins to 
Siah1, and to elucidate the interaction sites and mechanisms. Initial objectives were to 
express and purify soluble proteins for subsequent interaction studies using size 
exclusion chromatography (SEC). In addition, the crystal structures of apo-proteins and 
in complex with Siah1 were sought to characterise interaction interfaces and gain a 
better understanding of their cellular roles.     
5.3 Interaction studies 
5.3.1 Substrates 
Protein constructs of CtIP, TRB3, Kid, and PHD3 (Table 5.1) were designed according 
to the published information on Siah1 interaction regions and also bioinformatic 
analysis using web-based services for protein structure prediction Phyre2 and I-
TASSER (Kelley and Sternberg, 2009; Zhang, 2008). The genes encoding these 
constructs were purchased from a commercial vendor and were then inserted into a 
pET15b-TEV vector for protein expression following the same protocol as for Siah1 
(see section 2.2-2.4). CtIP and TRB3 expressed insolubly (Table 5.1), even when 
expressed together with the N-terminally attached solubility enhancing proteins such as 
maltose-binding protein and glutathione-S-transferase. Kid and PHD3 had a low yield, 
exhibited precipitation and interacted with E.coli proteins, resulting in insufficient final 
yield for further experiments with Siah1. Therefore, the binding of these proteins to 
Siah1 could not be investigated further. 
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Protein UniProt No. Constructs Expression 
CtIP Q99708 668-897 Insoluble 
TRB3 Q96RU7 66-358 / 66-318 Insoluble 
Kid Q14807 435-665 Low/ impure 
PHD3 Q9H6Z9 1-239 Low/ precipitates 
Table 5.1 Protein constructs and their expression. 
5.3.2 SIP 
Full-length SIP was expressed and purified as described in sections 2.3 and 2.4. SIP 
eluted from a size exclusion column as a single species displaying a mass of about 94 
kDa (Figure 5.1). This value equates to 3.6 times the MW of the monomer, which is 
consistent with previous gel filtration studies that reported SIP self-association 
(Matsuzawa and Reed, 2001). The crystal structure of SIP-S subsequently revealed that 
SIP forms a dimer (Santelli et al., 2005). SIP possibly displays a higher MW on a gel 
filtration column due to its elongated rod like shape. However, one study also observed 
the presence of monomer under certain buffer conditions (Bhattacharya et al., 2005). 
The purified SIP was investigated with DSF, which suggested the protein was folded 
and displayed the highest melting temperature of 61 ºC in the buffers tested. SIP 
interaction with Siah1 was tested by combining proteins together at 1:1 stoichiometry 
and incubating the sample overnight prior to its analysis on a size exclusion column. 
The results are shown in Figure 5.1. GF chromatogram showed the presence of two 
peaks. SDS-PAGE analysis revealed that the first peak of higher MW contained both 
proteins. The second peak with approximate mass of 49 kDa contained solely Siah1. 
The presence of Siah1 in fractions eluting at higher MW indicates the formation of 
complex with SIP. However, the ratio of each molecule in a complex could not be 
determined. For example, the Siah1 dimer binding two molecules of SIP would result in 
a complex with MW of 97 kDa, whereas the peak conformed to assembly with 
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approximate mass of 133 kDa. In addition, the bands on SDS-PAGE gel corresponding 
to SIP and Siah1 are not proportional, suggesting the sample is not homogeneous. Siah1 
interaction with SIP might be transient, where equilibrium is established between Siah1-
SIP complex and SIP homodimer. Attempts to crystallise SIP individually and in 
complex with Siah1 proved unsuccessful.      
 
Figure 5.1 Size exclusion chromatography for Siah1 and SIP.  
Three GF runs are superimposed: Siah1+SIP (red), SIP (blue), Siah1 (Green). SDS-PAGE gel is showing 
fractions from peak I of Siah1 run together with SIP. Siah1 elution volume is decreased in the presence of 
SIP compared to when run individually, thereby indicating formation of Siah1-SIP complex. 
    
5.3.3 PEG3-SCAN 
The gene encoding the SCAN domain of PEG3 (amino acids 40-130) was sub-cloned 
into the pET15b-TEV plasmid and transformed into E.coli for protein expression (see 
sections 2.2 and 2.3). The protein was purified according to the protocol in section 2.4. 
The protein eluted from a GF column as a single species with a mass of approximately 
30 kDa. The theoretical mass of PEG-SCAN is 11.4 kDa; thereby its oligomeric state 
could not be determined from a GF run. DSF analysis suggested the presence of a 
globular SCAN domain, which displayed a melting temperature of 52 ºC in a number of 
buffers. Since no buffer appeared to enhance stability the protein was left in the GF 
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buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl). The association between PEG3-
SCAN and Siah1 was tested in SEC by combining protein samples together at 1:1 
stoichiometry. The mixture was left overnight at 4 oC, before it was run on a GF 
column. However, there was no evidence of complex formation (Figure 5.2). In 
addition, the interaction was tested using protein-observed NMR, which was performed 
by Dr. Navratna Vajpai (AstraZeneca). The NMR experiment was done under the 
following conditions, where 100 µM of 15N-labeled Siah1 was mixed with 100 µM of 
unlabeled PEG3 in 50 mM HEPES pH 7.5, 50 mM NaCl, and 5 % D2O buffer. The 
chemical shift perturbations in the 2D 1H-15N HSQC spectra of 15N-labelled Siah1 were 
monitored upon addition of PEG3. The data showed no differences in chemical shifts in 
the 1H-15N HSQC spectra once PEG3-SCAN was added (data not shown), thereby 
indicating an absence of interaction between the proteins. The PEG3-SCAN sample was 
used for subsequent crystallisation, as its structure might give insight into the role this 
domain plays within the PEG3 protein.   
 
Figure 5.2 Size exclusion chromatography for Siah1 and PEG3-SCAN.  
Sample containing Siah1 together with PEG3-SCAN at 1:1 stoichiometry was run on size exclusion 
column. Siah1 and PEG3-SCAN eluted in two separate peaks. Collected fractions were analysed on SDS-
PAGE gel.  
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5.4 PEG3-SCAN crystallisation and data collection 
Crystallisation screening of PEG3-SCAN was carried out with the high-throughput 
Phoenix liquid handling system (Art Robbins Instruments/ Rigaku) and several 
commercially available screens (see section 2.5.3). 100 nL of protein sample at ~16.5 
mg mL-1 were mixed in sitting-well plates with 100 nL of reservoir solution against 70 
µL of the same reservoir solution. Crystals grew within a day in many conditions that 
contained polyethylene glycol (PEG) of different molecular weight. These 
crystallisation conditions were scaled up from these nano-drops to micro-drops of total 
volume 4 µL. However, the rod-shaped crystals that were observed were small, 
approximately 0.1 x 0.02 x 0.02 mm, and gave poor diffraction. While preparing more 
protein for use in crystal optimization it was observed that larger crystals actually 
formed spontaneously when the protein was concentrated in the GF buffer using 
Vivaspin 20 concentrators with a 3,000 MW cut off (Sartorius Stedim Biotech). 
Hexagonal bipyramid crystals, reaching 0.2 x 0.2 x 0.2 mm dimensions, formed within 
minutes (Figure 5.3). The average protein concentration in the centrifugal device was 5 
mg mL-1, but likely to have been considerably higher near the membrane where crystal 
nucleation occurred. The selection of a suitable cryoprotectant required extensive 
screening and optimization. The use of glycerol, ethylene glycol and paratone-N 
produced either poor diffraction or pronounced ice rings. The most favourable 
cryoprotectant was PEG200. Crystals were transferred into cryo-solution of PEG200 
and GF buffer at 1:1 ratio prior to flash cooling for X-ray diffraction studies. 
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Figure 5.3 PEG3 crystals.  
(A) The crystals formed during protein concentration within minutes. (B) The crystals diffracted in-house 
to 1.95 Å. 
 
5.4.1 Structure solution and refinement 
Diffraction data were collected in-house with a Micromax-007 rotating anode generator 
(copper Kα, λ = 1.5414 Å) coupled to an AFC11 Saturn 944+ CCD detector (Rigaku). 
The data were indexed and integrated with iMOSFLM (Battye et al., 2011) and scaled 
with AIMLESS from the CCP4 program suite (Winn et al., 2011). The structure was 
solved by molecular replacement with Phaser (McCoy et al., 2007) using a poly-Ala 
model of the SCAN domain dimer from the mouse zinc finger protein 206 (Zfp206, 
PDB code 4E6S (Liang et al., 2012)) that shares 38 % sequence identity with the PEG3-
SCAN domain. The output model was subjected to a round of rigid body and restrained 
refinement using REFMAC5 (Murshudov et al., 2011). The poly-Ala model was 
modified to the sequence of human PEG3-SCAN based on inspection of electron and 
difference density maps in COOT (Emsley et al., 2010). Several residues and side 
chains for which there was no convincing electron density were deleted. Additional 
rounds of restrained least-squares refinement followed, interspersed with map 
inspection and model manipulation. The refinement used the default geometry and B-
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factor restraint weights. Neither non-crystallographic symmetry (NCS) restraints nor 
TLS (Translation/ Libration/ Screw) were used in refinement. A number of ligands 
(ethylene glycol, diethylene glycol and triethylene glycol) were included in the model 
on the basis of the difference density and chemical environment, and refined 
successfully. These molecules are likely to be decomposition products or impurities of 
the PEG200 cryoprotectant. The final model also includes multiple side chain 
conformers and water molecules. The stereochemistry of the model was checked using 
MolProbity (Chen et al., 2010). Crystallographic statistics are given in Table 5.2.  
 PEG3-SCAN 
 
Space group P65 
Unit cell dimensions: a, b, c (Å) 83.61, 83.61, 55.23 
Resolutiona (Å) 13.8 - 1.95 (2.00 - 1.95) 
No. of reflections 453776 (23734) 
Unique reflections 16090 (1143) 
Completeness (%) 99.7 (99.8) 
Multiplicity 28.2 (20.8) 
<I/σI> 38.2 (9.7) 
Wilson B (Å2) 20.6 
Residues 
 
 
 
 
Chain A 40-127 
Chain B 40-129 
Water/ ethylene glycol/ diethylene glycol/ triethylene glycol 155 / 21 / 4 / 2  
Rmergeb (%) 7.0 (31.8) 
Rworkc, Rfreed (%) 17.2 / 22.4 
Mean B-factors (Å2) 
 
 
Protein  26.6 
Ligands and waters 40.6 
Ramachandran plote (%) 
 
 
 
 
 
 
Most favoured  98.4 
Additional allowed  1.6 
Outliers  0.0 
R.m.s.d. on ideal valuesf  
Bond length (Å) / bond angles (º) 0.02 / 2.02 
Table 5.2 Crystallographic statistics of PEG3-SCAN. 
a. Values in parentheses refer to the highest resolution shell. b. Rmerge = ∑hkl∑i|Ii(hkl) - <I(hkl)>|/ ∑hkl∑i 
Ii(hkl); where Ii(hkl) is the intensity of the ith measurement of reflection hkl and <I(hkl)> is the mean 
value of Ii(hkl) for all i measurements. c. Rwork = ∑hkl||Fo|-|Fc||/∑|Fo|, where Fo is the observed structure 
factor and Fc is the calculated structure factor. d. Rfree is the same as Rwork except calculated with a subset, 
5 %, of data that are excluded from refinement calculations. e. (Chen et al., 2010). f. (Engh and Huber, 
1991).  
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5.5 PEG3-SCAN structure 
5.5.1 Structure quality 
Crystals of human PEG3-SCAN belong to space group P65, with a VM value of 2.44 Å3 
Da-1 and solvent content of approximately 50 % for an asymmetric unit comprising two 
polypeptide chains. The polypeptides are arranged as a symmetrical dimer consistent 
with previously solved structures of SCAN domains (Liang et al., 2012; Ivanov et al., 
2005; Peterson et al., 2006). The crystals diffract to a resolution of 1.95 Å and 
continuous, well-defined electron density is observed for majority of the structure, with 
an exception of a few residues at the C-terminus. The final model also contains two 
extra residues (His and Met) at the N-terminus, which were left from a cleaved histidine 
tag. A Ramachandran plot indicates that 98.4 % of the amino acids are located in the 
most favoured region with no outliers.  
5.5.2 Overall structure 
The human PEG3-SCAN domain resembles a broadened V-shaped structure (Figure 
5.4A), with approximate dimensions of 50 x 25 x 25 Å. Two V-shaped monomers in a 
dimer are located side by side to form a dimer with dimensions of 50 x 37 x 30 Å. The 
subunit consists of five α helices, with primary sequence and assigned secondary 
structure displayed in Figure 5.4B. The N-terminal sub-domain is formed from helices 
α1 and α2 which form one of the two arms of the V (Figure 5.4A). The other half, the 
C-terminal domain packs together α3, α4 and α5. The domain assemblies with the N-
terminal sub-domains interacting with partner C-terminal sub-domains (Figure 5.5). A 
least-squares superposition of subunits with LSQKAB (Kabsch, 1976) gives the r.m.s.d. 
(root-mean-square deviation) of 0.57 Å for 90 Cα atoms, which shows there are no 
major conformational differences between the two subunits.  
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Figure 5.4 The structure of PEG3-SCAN.  
(A) Overall structure of PEG3-SCAN homodimer is shown as ribbons with one subunit green, the partner 
purple. The N- and C- termini as well as the five α-helices of each monomer are labelled accordingly. (B) 
Diagram is showing sequence alignment of PEG3-SCAN with other SCAN proteins from PDB. PEG3-
SCAN residues that are strictly conserved in Zfp206 (PDB: 4E6S), Znf24 (PDB: 3LHR), Znf42 (PDB: 
2FI2) and Znf174 (PDB: 1Y7Q) are encased in black, while residues sharing similar properties in five 
proteins are encased in grey. Five α-helices are shown as cylinders (purple) and are numbered 
accordingly. The numbers that are shown above the secondary structure mark residues in the full length 
PEG3 protein.  
 
The total accessible surface area of the individual subunits as determined by PISA 
(Krissinel and Henrick, 2007), is about 7400 Å2 of which 1700 Å2 involved in forming 
dimer interface. Thus, approximately 23 % of the surface area of each subunit 
participates in dimerisation. PISA estimates the free energy of dissociation (ΔGdiss) to be 
19.4 kcal mol-1, suggesting that the assembly is thermodynamically stable. This is 
consistent with the observation of a stable oligomer in solution. These surface areas are 
equivalent in other SCAN structures. For instance, the interface area and ΔGdiss for the 
Znf24 dimer (PDB code 3lhr) are 23 % and 21.8 kcal mol-1, respectively.  
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Figure 5.5 Overlay of SCAN domain 
structures.  
These are PEG3-SCAN (purple), Zfp206 
(PDB 4e6s, cyan), Znf24 (PDB 3lhr, 
green), Znf42 (PDB 2fi2, yellow) and 
Znf174 (PDB 1y7q, grey).  
 
 
 
 
There are currently four SCAN domain structures deposited in the PDB, two crystal 
structures and two determined by solution NMR. Their sequence conservation with 
PEG3-SCAN is presented in Figure 5.4B. A large degree of structural conservation is 
observed between these SCAN domain structures and PEG3-SCAN (Figure 5.5), with 
calculated r.m.s.d. values shown in Table 5.3. Two regions of structural non-alignment 
are at the N- and C-terminal ends, which are more flexible than the core of the 
molecule. The other flexible segment is α4, which is positioned away from the dimer 
interface and whose sequence is least conserved among five α-helices. The r.m.s.d. 
values for overlaid PEG3-SCAN with the two structures derived by NMR (Znf42 and 
Znf174) are higher than for the X-ray structures. This is because the NMR structures 
contain greater uncertainties and 20 conformers were averaged during superimposition 
with PEG3-SCAN domain.  
Protein 
name 
PDB 
codes 
R.m.s.d (Å)  R.m.s.d alignment 
length 
Sequence 
identity (%) 
Zfp206 4E6S 1.57 157 38 
Znf24 3LHR 1.51 164 48 
Znf42 2FI2 2.85 155 35 
Znf174 1Y7Q 2.87 167 43 
Table 5.3 Structure and sequence similarity of PEG3-SCAN and other SCAN domains. 
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These included crystal structures of Zfp206 and Znf24, and solution NMR structures of 
Znf42 and Znf174. R.m.s.d. calculations were carried out with PDBeFold using 
secondary structure matching (Krissinel and Henrick, 2004) with the PEG3-SCAN 
dimer in the superposition. Sequence alignment was performed with ClustalW2 using 
residues 40-130 of the full-length PEG3 against the core of the SCAN domain, as well 
as 2-5 flanking residues, of other proteins.  
5.5.3 Residues forming the SCAN dimer interface 
The PEG3-SCAN homodimer consists of an extended network of interactions, such as 
hydrogen-bonding, salt-bridge interactions and van der Waals forces, which weave 
together both subunits. The residues found at the dimer interface in all five structures 
are highly conserved, even though the overall sequence conservation among SCAN 
domains is only 40-50 % (Figure 5.4B). The intermolecular interactions are 
predominantly formed by residues located on α1 and α2 of the N-terminal segment of 
one subunit and amino acids on α3 of the C-terminal subdomain of the second. 
Sequence homology is highest between helices α2 and α3, with their residues 
participating in either direct inter-subunit contacts or mediating the chains of hydrogen 
bonding that involve a number of residues. For instance, the carboxyl group of Glu43 
donates a proton to stabilise the imidazole ring of His46 located on the same helix α1 
(Figure 5.6A). The later makes another hydrogen bond to Glu92 on α3, which is located 
close to the NCS two-fold axis. Glu92 in turn forms a salt bridge with Arg50 and 
another bond with well-ordered and buried water molecule. The Arg50 also interacts 
with Gln93 of the partner subunit and a water molecule, which acts as a bridge to link 
Arg50 to the partner subunit Glu92. Arg68 forms an inter-molecular salt bridge with 
Glu87, linking α2 and α3 from two different subunits together (Figure 5.6B). The 
aforementioned residues are highly conserved within SCAN domains and observed to 
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establish similar hydrogen bonding contacts. In addition, mutation of both the 
equivalent Arg50 and Arg61 residues to alanines in Zfp206 destabilizes its 
heterodimerisation with Zfp110 (Liang et al., 2012). Thus, these invariant residues seem 
to play an important role in both homo- and heterodimerisation. Other residues involved 
in inter-molecular bonding include Lys82, whose side chain interacts with Pro77 and 
Arg61 with Glu115 (Figure 5.6B). The later makes a salt-bridge interaction, which 
links α2 with the partner subunit α5. The later pair of residues is substituted to a similar 
lysine glutamine pair in some SCAN domain sequences. 
 
 
 
Figure 5.6 The dimer interface of PEG3-SCAN (I).  
(A) A network of hydrogen-bonds is established between conserved residues lining the dimer interface. 
(B) A second cluster of hydrogen bonding and salt bridge interactions at the dimer interface. Water 
molecules are shown as red spheres. Atomic positions are coloured: C (purple or green), O (red), and N 
(blue). 
 
A number of the interactions present in the PEG3-SCAN dimer are absent in other 
structures. For example, a hydrogen bond is formed between the side chain of Tyr94 on 
one subunit and the main chain of Pro60 (Figure 5.7A) on the partner. This interaction 
does not happen in other structures where the tyrosine is swapped for phenylalanine. In 
addition, PEG3-SCAN establishes a salt bridge between Glu56 and non-conserved 
Lys101. Glutamate is present at this position in most other SCAN domains. Such subtle 
structural variations may confer the preference of different SCAN domains to form 
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homo- and heterodimers. 
 
Figure 5.7 The dimer interface of PEG3-SCAN (II).  
(A) A hydrophobic patch is present at each end of the assembly to stabilize the dimer. The conserved 
Tyr94 extends across the dimer interface, contributes to hydrophobic interations and makes a hydrogen 
bond with the carbonyl of Pro60. (B) A group of conserved, aliphatic and aromatic residues form a 
hydrophobic core at the centre of the dimer. 
 
Further to the water molecules described above, with their central location to mediate a 
number of inter-subunit interactions, other water molecules are positioned at the 
periphery of the dimer interface. These seem to be less ordered and likely do not 
contribute significantly towards stabilisation of the dimer, taking into consideration the 
high percentage of the surface area involved in direct association. 
The hydrogen interactions are further strengthened by hydrophobic contacts. For 
example, one hydrophobic patch includes Leu75, Ile85, Ile86 and Leu89, which are 
located on α2 and α3, and make interactions to equivalent residues in opposing 
monomer (Figure 5.7B). In another patch, a conserved Tyr54 in one monomer buries its 
side chain into a hydrophobic core of Tyr94, Ile97, Ile98, Pro99, Leu102 and Leu121 of 
α3-α5 of the second monomer in a dimer (Figure 5.7A). Other hydrophobic residues 
extending across the dimer interface include Leu52, Leu64, Leu67, Val90 and Val118. 
In addition, the superposition of SCAN domain structures also helps explain the role of 
other conserved residues. For instance, the strictly conserved Pro60 and Pro98 introduce 
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kinks at the start of α2 and α4, respectively. Thus, the sequence alignment and structural 
overlay of PEG3-SCAN with available SCAN domain structures shows overall fold 
homology and reveals the key residues for forming PEG3-SCAN dimer.  
5.5.4 Function of the SCAN domain 
Some transcription factors commonly form complexes to control the expression of 
target genes. For instance, the proto-oncogene Jun, which is a member of the basic 
region-leucine zipper (bZIP) family, controls gene transcription in a precise way by 
forming homo- and heterodimers. The dimerisation mode and interactions with given 
binding partners regulate its activity and DNA-binding site preferences (Halazonetis et 
al., 1988). Certain Cys2-His2 zinc finger containing transcription factors are also known 
to be regulated by a similar mechanism via their protein-protein binding BTB/POZ 
domain. Self-oligomerisation of this domain in the GAGA transcription factor promotes 
DNA binding affinity and specificity (Espinas et al., 1999). The SCAN domain may 
have a similar function in regulating mammalian gene expression by facilitating both 
homo- and specific hetero-dimerisation of Cys2-His2 zinc finger proteins. Currently 
there is no evidence that would indicate SCAN domain’s involvement in direct 
transcriptional activation or repression. The ability of PEG3-SCAN to homodimerise in 
vitro provides the possibility that the same can happen with full-length protein inside 
the cell. Therefore, it might bind to at least some target genes as a homodimer. In 
particular, formation of the homodimer might enable PEG3 to bind palindromic DNA 
motifs. The support for this hypothesis comes from the transcription factor Zfp206 that 
can form a homodimer using its SCAN domain for binding to a palindromic sequence 
(Liang et al., 2012; Yu et al., 2009). A search for PEG3 DNA interaction motifs 
revealed a 15 base pair non-palindromic sequence, which was subsequently validated by 
electromobility shift and promoter assays (Thiaville et al., 2013). Even though only the 
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full-length motif exhibited the maximal binding, PEG3 was also detected to interact 
with the partial sequence as well as to other segments with degenerate sequence.  
There are currently four known isoforms of PEG3. It is possible that isoform specificity 
affects the DNA binding selectivity and affinity. For example, one isoform contains 
only two Cys2-His2 zinc finger motifs, while in two others the SCAN domain is absent 
altogether. Thus, cellular expression of PEG3 with a different number of zinc finger 
motifs as well as with and without the SCAN domain can potentially act as another 
level of regulation. A number of studies have shown that at least some SCAN domain 
members are able to selectively bind to other SCAN members (Williams et al., 1999; 
Sander et al., 2000; Schumacher et al., 2000; Liang et al., 2012). However, the 
possibility of PEG3-SCAN domain to heterodimerise has not been investigated to date. 
Residues participating in inter-subunit binding in the Zfp206 dimer structure were 
closely matched and had similar spatial location to the residues of an overlaid PEG3-
SCAN subunit. This indicates that PEG3-SCAN domain might form heterodimers with 
Zfp206 and with other SCAN domain containing proteins. Future studies, investigating 
the binding partners of PEG3-SCAN are needed to help determine the function of PEG3 
in gene regulation.  
5.6 Discussion 
Siah1 is a scaffolding protein reported to interact with a large number of different 
proteins (Qi et al., 2013). Many are the substrates for ubiquitination and subsequent 
proteasomal degradation. Others regulate Siah1 activity and some assemble together 
with Siah1 into multi-protein E3 ligase complexes. In attempt to validate these and 
characterise the relevant protein-protein interactions, a number of Siah1 substrates and 
its binding partners in multi-protein complexes were investigated. Initial studies 
concentrated on four target proteins: CtIP, TRB3, Kid and PHD3. However, attempts to 
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produce soluble proteins in E.coli in sufficient amounts for the interaction studies were 
unsuccessful. Future studies may try to co-express these proteins together with Siah1, 
explore a different expression system or use alternative protein constructs. 
SIP was shown to interact with Siah1 in an E3 ligase complex, where it physically links 
the ubiquitination activity of Siah1 with Skp1 (Schneider and Filipek, 2011). The 
binding site for Siah1 is situated at the N-terminal segment of SIP, which also contains 
a Siah1 binding motif within its sequence (Santelli et al., 2005). This study aimed to 
assess whether other SIP segments outside the N-terminal domain were involved in the 
interaction with Siah1. The interaction between Siah1 and a full-length SIP was initially 
confirmed by the presence of a complex on a gel filtration column. However, 
subsequent attempts to crystallise SIP in complex with Siah1 and alone were 
unsuccessful. Crystallisation might be hindered by the transient nature of the SIP-Siah1 
interaction or by the unstructured C-terminal region of SIP. The use of other 
components such as Skp1 and Ebi to stabilise an E3 ligase complex may be considered 
in future studies. 
Two previous studies reported the interaction between PEG3 and Siah1 (Relaix et al., 
1998; Jiang et al., 2010), and showed that they cooperate together to induce p53 
independent apoptosis. However, the studies were not conclusive so the interaction was 
investigated here by SEC and NMR. However, no association was observed between 
the proteins either on a size exclusion column or in the 2D NMR experiment using 15N-
labelled Siah1. The absence of the interaction indicates that residues outside the SCAN 
domain might be needed for binding to Siah1. However, there are no other obvious 
Siah1 binding motifs nearby and the sequences on both ends of SCAN domain are 
predicted to be disordered. The PEG3-SCAN structure reveals that the 58VGP60 motif is 
located on the loop just prior to α2 (Figure 5.7A). The proline is buried within a dimer 
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interface, while the side chain of valine is pointing to the side of α2.  If this is indeed a 
Siah1 consensus site, then conformational changes might be required to allow for 
complex formation. It is possible the conditions under which the experiments were 
performed were not suitable for such changes to occur or the presence of the VxP 
sequence might be a coincidence. The data obtained cannot exclude the possibility that 
interaction occurs though other sites outside the SCAN domain, thereby additional 
studies are needed with longer fragments of PEG3. 
The determined structure of the SCAN domain from PEG3 revealed it forms a stable 
homodimer. The structure shared high structural and sequence homology with other 
known SCAN domains and uncovered the key residues forming the dimer interface. The 
ability to dimerise suggests PEG3 might form homo- and heterodimers with other 
SCAN domain containing proteins to control gene expression in a combinatorial 
fashion. However, further studies are required to test this hypothesis.  
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6.1 Background 
Metallocarboxypeptidases (MCPs) hydrolyse peptide bonds in target proteins to cleave 
C-terminal amino acids. They are classified into different families according to their 
sequence homology, catalytic mechanism and function (Gomis-Rüth, 2008; Rawlings et 
al., 2012). One of the more diverse families is called M14. Its members contain a single 
catalytic Zn2+ in the active site, which is held in place by two histidine residues, one 
glutamate and a water molecule. The family is grouped into four subfamilies known as 
M14A, B, C and D. One of the earliest and best studied family member being bovine 
carboxypeptidase A (CP-A; Christianson and Lipscomb, 1989). In general, M14A and 
M14B carboxypeptidases function either within the secretary pathway or are themselves 
secreted into the extracellular space. Members of the M14A subfamily are produced as 
inactive enzyme precursors that are activated following cleavage of N-terminal 
segments to reveal the active site. In contrast, the M14B subfamily members are 
produced as active enzymes with a transthyretin-like domain at the C-terminus. These 
proteins often contain additional domains and even repeats of the carboxypeptidase 
domain (Vendrell et al., 2004). The M14C group contains the bacterial orthologs of D-
glutamyl-(L)-meso-diaminopimelate peptidase I and process components of the 
bacterial cell wall (Hourdou et al., 1993). They resemble the M14A group in that they 
also carry an N-terminal extension. 
The M14D subfamily has only recently been described and there is still little 
information available about their structure and function. They are also known as 
cytosolic carboxypeptidases (CCPs) due to their cytosolic localisation. A search of 
available genomic sequences revealed CCPs are present in most organisms, with an 
exception of Archaea, Fungi and higher plants (Otero et al., 2012). The number of CCP 
paralogs varies between species. For example, six isoforms were identified in mammals, 
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two in nematodes and just one in proteobacteria, and only in Gram-negative bacteria 
containing flagella (Rodriguez de la Vega et al., 2007). Four mammalian CCP proteins 
and a homologue from Caenorhabditis elegans, called CeCCPP-6, have been identified 
as deglutamylases (Kimura et al., 2010; Rogowski et al., 2010). They reverse 
glutamylation, process, a post-translational modification where glutamate residues are 
attached to a target protein. This modification was first observed on α- and β-tubulin, 
and later found to occur on telokin and myosin light chain kinase 1 (Edde et al., 1990; 
Rudiger et al., 1992; Rogowski et al., 2010). Mammalian deglutamylases can be further 
distinguished by their substrate preference. For example, CCP1 and its functional 
homologs CCP4 and CCP6 cleave individual glutamates from the main chain, while the 
CCP5 isoform removes the branching point glutamates. In addition to this activity, 
CCPs might process other C-terminal amino acids. For example, mammalian CCP2 was 
recently reported to cleave the C-terminal tyrosine from α-tubulin (Sahab et al., 2010). 
Less is known about the functional activity of the bacterial CCPs. A recent study of the 
Pseudomonas aeruginosa CCP (PaCCP) did not detect any activity against known 
carboxypeptidase substrates, with the authors suggesting that activation might require a 
conformational change or PaCCP might be highly substrate specific (Otero et al., 
2012). Although the function of bacterial CCPs is not understood, the gene encoding the 
PaCCP was identified to be essential for the pathogen to establish a lung infection in a 
murine model (Winstanley et al., 2009). Therefore, CCPs might represent a potentially 
novel class of antibacterial drug targets and require further investigation.    
6.2 Aims 
The aim of the study was to structurally characterise recombinant Burkholderia 
cenocepacia CCP (BcCCP). BcCCP is the closest ortholog of mammalian CCP5 and its 
function is unknown. The elucidation of its structure would allow us to compare BcCCP 
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with PaCCP (Otero et al., 2012) and two other bacterial CCP structures in the Protein 
Data Bank (PDB) together with mammalian carboxypeptidases of defined substrate 
specificity. Together they should provide an insight into the conserved residues and 
motifs forming a stable CCP fold and might inform about BcCCP substrate specificity.        
6.3 Recombinant BcCCP expression and purification 
The gene encoding the full-length protein (residues 1-384) was amplified using genomic 
DNA from B. cenocepacia J2315 (Laboratory for Microbiology of the Faculty of 
Sciences of the Ghent University (LMG) 16656 strain) and cloned into pET15b-TEV 
that incorporates an N-terminal histidine tag (see section 2.2). The protein was 
expressed in ArcticExpress (DE3) cells and was purified as described in section 2.4 still 
carrying the His-tag. The typical protein yields were in excess of 20 mg L-1 of culture. 
BcCCP monomer has a theoretical MW of 45.3 kDa, but the protein eluted from a GF 
column with a mass of around 140 kDa (Figure 6.1). Native PAGE gel showed a band 
of around 146 kDa, thereby suggesting oligomer formation. The subsequent SEC-
MALS experiment showed the protein eluted with a mass of 174 kDa (data not shown), 
indicating that BcCCP forms a tetramer. Gene cloning, SEC-MALS and crystallisation 
experiments were carried out by Thomas Eadsforth (University of Dundee). 
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Figure 6.1 Size exclusion chromatography and native PAGE analysis. 
BcCCP eluted with MW of 140 kDa and displayed a 146 kDa band on native PAGE gel. The calibration 
curve was plotted using five standards labelled A to E. The 4-16 % Native PAGE gel shows protein (lane 
1) and MW standards (lane 2). 
  
6.4 Crystallisation and data collection 
A crystallisation screen utilising commercially available formulations and was set up 
with a Phoenix liquid handling system (Art Robbins Instruments / Rigaku) (section 
2.5.3). 100 nL-1 of protein solution at 10 mg mL-1 in 100 mM Na(CH3CO2) pH 5.0, 150 
mM NaCl and 0.5 mM ZnSO4 were mixed with the same volume of reservoir and 
equilibrated against 70 µL-1 reservoir at 20 ºC. Orthorhombic rod-shaped crystals, with 
approximate dimensions of 30 x 10 x 10 µm, were observed after three days in 
conditions containing a reservoir of 0.2 M Li2SO4, 25 % PEG 3350 and 0.1 M Bis-Tris 
pH 5.5 (Figure 6.2). A single crystal was soaked in a cryoprotectant solution containing 
the reservoir buffer with 20 % glycerol prior to flash cooling at -173 ºC. Crystal was 
initially characterised in-house with a MicroMax-007 rotating-anode generator and R-
AXIS IV++ dual image plate detector (Rigaku), prior to storage in liquid nitrogen. X-ray 
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diffraction data were subsequently collected on the ID23-2 microfocus beamline at the 
European Synchrotron Radiation Facility (ESRF). The small size of the crystal and its 
unit cell dimensions, with a particularly long c axis, required the use of a microfocus 
beam of approximately 10 microns together with a helical data collection strategy. 
These strategies, combined with a short exposure time of 0.6 s and a MAR mosaic 225 
mm (MAR Research) charge-coupled device (CCD) detector, allowed good separation 
of the reflections, appropriate sensitivity and low X-ray damage, permitting a complete 
data set collection. Data were integrated and scaled using MOSFLM (Leslie, 2006) and 
SCALA (Evans, 2006).  
 
Figure 6.2 BcCCP crystals.  
(A) Orthorhombic rod-shaped crystals formed after three days. (B) The crystal diffracted at ESRF 
synchrotron using a microfocus beamline to 1.90 Å. 
 
6.5 Structure solution and refinement 
The structure was solved by molecular replacement using a poly-Ala model of the 
monomer of a CCP structure from Burkholderia mallei (BmCCP), which shares 85 % 
sequence identity (PDB code 3k2k). Rotation and translation functions were solved 
using Phaser (McCoy et al., 2007). Four polypeptide chains were placed within the 
asymmetric unit and upon the inspection of the molecular packing in Coot (Emsley et 
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al., 2010) showed no steric clash. Rigid-body refinement was carried out in REFMAC5 
(Murshudov et al., 2011). The resolution limits were initially set from 144.5 Å to 2.5 Å 
and the Rfree was 33.3 % following rigid-body refinement. Ten cycles of restrained 
refinement were then performed with the resolution extended to 1.9 Å. The Rwork and 
Rfree decreased to 24.6 % and 28.6 %, respectively. The density maps for chain A were 
inspected in Coot, with some absent side chains rebuilt, and those out of density deleted. 
Chain A was rotated and translated to provide the other three polypeptides in the 
asymmetric unit and the four Zn2+ ions were included. At this stage, it was decided to 
incorporate the strategies utilised in the PDB_REDO protocols to help with efficient 
refinement of a sizeable model containing in excess of 1500 amino acids (Joosten et al., 
2012). Thus, the model was subjected to several cycles of PDB_REDO refinement by 
Robbie Joosten (Netherlands Cancer Institute) followed again by the density maps 
inspection and rebuilding. Translation/ libration/ screw analysis (TLS; Painter and 
Merritt, 2006) was applied to create a TLS group description and the B-factors were 
reset to the Wilson B-factor. Following TLS refinement, the B-factor restraint weight 
was optimised with the final value of 0.30 being lower than default option. Afterwards, 
30 cycles of restrained refinement with different X-ray weights were tested, with the 
weight 0.10 resulting in the most improved model. The model was modified to include 
side chains and water molecules, while Zn2+ ions were placed into the correct chains 
prior to running the second round of PDB_REDO refinement. The output model was 
inspected and multiple conformers were added at this point. Further rounds of restrained 
refinement followed, using the B-factor and geometric restraint weights established with 
PDB_REDO. Tight local non-crystallographic symmetry (NCS) restraints were imposed 
at the onset of the refinement and were kept until the final round of calculations. The 
model geometry and quality were analysed with MolProbity (Chen et al., 2010). The 
crystallographic statistics are shown in Table 6.1. 
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 BcCCP 
Space group P212121 
Unit cell dimensions: a, b, c (Å) 62.90, 85.95, 289.02 
Resolutiona (Å) 40 - 1.90 (2.00 - 1.90) 
No. of reflections 516512 (74589) 
Unique reflections 124234 (17924) 
Completeness (%) 99.9 (100.0) 
Multiplicity 4.2 (4.2) 
<I/σI> 8.4 (2.7) 
Wilson B (Å2) 13.3 
Residues 
 
 
 
 
Chain A 2-156, 159-383 
Chain B 2-318, 320-384 
Chain C 2-156, 159-314, 320-384 
Chain D 1-315, 320-384 
Water / glycerol / ethylene glycol  1062 / 9 / 7  
Diethylene glycol / Cl- / Zn2+ / acetate 1 / 3 / 4 / 4 
Rmergeb (%) 13.0 (48.4) 
Rworkc, Rfreed (%) 16.4 / 20.5 
Mean B-factors (Å2) 
 
 
 
Protein 
 
 
 
 
6.7   
Ligands and waters 26.2 
Ramachandran plote (%) 
 
 
 
 
Most favoured 96.9 
Additional allowed  2.9 
Outliers 
 
0.2 
R.m.s.d. on ideal valuesf  
Bond lengths (Å) / angles (º) 0.01 / 1.14 
Table 6.1 Crystallographic statistics of BcCCP. 
a. Values in parentheses refer to the highest resolution shell. b. Rmerge = ∑hkl∑i|Ii(hkl) - <I(hkl)>|/ ∑hkl∑i 
Ii(hkl); where Ii(hkl) is the intensity of the ith measurement of reflection hkl and <I(hkl)> is the mean 
value of Ii(hkl) for all i measurements. c. Rwork = ∑hkl||Fo|-|Fc||/∑|Fo|, where Fo is the observed structure 
factor and Fc is the calculated structure factor. d. Rfree is the same as Rwork except calculated with a subset, 
5 %, of data that are excluded from refinement calculations. e. (Chen et al., 2010). f. (Engh and Huber, 
1991).  
 
6.6 BcCCP structure 
6.6.1 General comments 
The BcCCP protein crystallised in space group P212121 with unit cell lengths a = 62.9Å, 
b = 85.9 Å, c = 289.0 Å. The asymmetric unit consists of four polypeptide chains with a 
VM value of 2.17 Å3 Da-1 and solvent content of about 45 %. Diffraction data were 
collected by exploiting the use of a microfocus synchrotron radiation beamline to 
accommodate the small size of the crystal and to help resolve the issue of a long unit 
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cell edge. The structure was solved by molecular replacement and then employed a 
slightly unconventional approach of PDB_REDO in order to carry out the efficient 
refinement of a relatively large asymmetric unit with data to high resolution. This 
procedure uses a range of automated protocols to test different models for B-factors, 
weighting restraints on geometry, optimised with respect to diffraction data parameters 
(Joosten et al., 2012). The approach was initially developed to improve the old 
structures held in the PDB by re-refining them using modern software.  
The majority of the residues are found within well-defined electron density. The only 
disordered regions include the N- and C-terminal residues, residues 157-158 in chains A 
and C, and a number of residues in the loop (315-320) of subunits B, C and D.  
A strong feature of 7 σ was observed in the difference density map in each active site 
near Arg226. Acetates derived from 50 mM sodium acetate present in the crystallisation 
conditions were modelled in. Analysis of the PaCCP (Otero et al., 2012; PDB code 
4a39) and CP-A structures (Christianson and Lipscomb, 1986, Mangani et al., 1992; 
PDB code 1cbx) in complex with guanidinoethylmercaptosuccinic acid and 
benzylsuccinic acid, respectively, showed that the carboxyl group of these ligands is 
located at the same position as this acetate.  
6.6.2 Quaternary structure 
BcCCP is a tetramer, forming a square-shaped structure with an opening in a centre. The 
tetramer is arranged as a dimer of dimers (labelled A:B and C:D in Figure 6.3), which 
is consistent with the structures of BmCCP and Shewanella denitrificans CCP (SdCCP, 
PDB code 3l2n). The only known exception is PaCCP, reported to be monomeric 
(Otero et al., 2012).  
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Figure 6.3 BcCCP tetramer. 
The structure is displayed as a semi-transparent van der Waals surface over the ribbon cartoon. Subunits 
are labelled A (yellow), B (green), C (cyan) and D (blue). Asterisks mark positions of disordered loops. 
 
The average solvent accessible surface area of each BcCCP subunit is approximately 
15500 Å2. The interface formed between two dimers in a tetramer (A:B and C:D) 
occludes 2800 Å2, while the interface between subunits A:C (and B:D) equates to 1900 
Å2. Therefore, about 9 % of the surface area of each subunit is involved in dimer 
formation, with further 6 % participating in associations between a dimer of dimers. The 
secondary structure elements forming the interface are shown in Figure 6.4. Two 
polypeptides in a dimer are stabilised by around 24 hydrogen bonds, nine salt bridges 
and van der Waals interactions. Some of the residues contributing to a dimer (A:B and 
C:D) include Gln127 and Glu117 on α1, Asp104 on a loop between β8 and β9, Ser105 
on β9, and Glu142 on a loop between β10 and β11 (not shown). There are about eight 
hydrogen bonds and two salt bridges between a pair of dimers in a tetramer. A few 
residues forming the interactions include Asp193 on a loop between α2 and α3, Lys186 
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on α2 and Arg201 on α3 (not shown). These residues are either conserved or substituted 
with equivalent in BmCCP and SdCCP, but they are not conserved in PaCCP. 
Superposition of Cα atoms of all four chains of BcCCP gives an r.m.s.d in the range 
0.23 – 0.35 Å, indicating that the errors associated with the structure are insignificant 
and subunits are essentially identical. Therefore, only subunit A is detailed, unless 
stated otherwise.      
Figure 6.4 Tetramer interface. 
(A) The interface between subunits in a 
dimer of dimers. (B) The interface 
between two dimers in a tetramer. The 
secondary structure elements lying at the 
interface are labelled. Disordered loops 
are marked with asterisks. The dashed 
line points to the N-terminal end, which 
is not visible on a cartoon.  
 
 
 
 
 
 
 
 
 
 
 
6.6.3 Subunit structure and comparison with other CCPs 
The structure of BcCCP contains two domains similar to other M14 family members. 
The N-terminal domain consists of residues Met1 – Glu112 and the remaining 272 
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residues form the CP domain (Figure 6.5). The N-terminal domain folds into a nine-
stranded antiparallel β-sandwich. Strands β2, β3, β5, β8 and β7 form one sheet and β1, 
β4, β9 and β6 the other. This domain of unknown function is specific for CCP proteins 
and absent in other carboxypeptidases. The domain might be contributing to folding, 
playing a regulatory role and/or might be involved in binding other proteins (Kalinina et 
al., 2007; Rodriguez de la Vega et al., 2007). The N-terminal domain is structurally 
conserved among CCPs, with a superposition of this domain from BcCCP and PaCCP 
giving an r.m.s.d value of 0.87 Å for over 109 Cα positions. 
 
Figure 6.5 The structure of BcCCP.  
(A) The tertiary structure of subunit A showing α-helices (magenta) and β-strands (orange). Zn2+ depicted 
as a grey sphere.  The N- and C-terminal positions are labelled, as are the α-helices and β-strands. A break 
in chain is marked with asterisks. (B) The primary and secondary structure of BcCCP. Residues that are 
strictly or highly conserved in BcCCP, BmCCP, SdCCP, PaCCP and CeCCPP-6 are enclosed in black and 
grey, respectively. Three residues that coordinate Zn2+ are marked with a yellow star. The three motifs of 
the N-terminal domain, which are conserved in CCP members, are enclosed in green boxes. 
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The CP domain of BcCCP consists of an α/β/α sandwich structure with a seven-stranded 
antiparallel β-sheet. The same structural fold is present in other M14 family 
carboxypeptidases such as bovine carboxypeptidase A (CP-A, Figure 6.6). An overlay 
of BcCCP and bovine CP-A (PDB code 6cpa; Kim and Lipscomb, 1990), which share 
about 20 % sequence identity, gives an r.m.s.d of 2.03 Å for 225 Cα positions. There is 
a good overall fit between the central cores of both structures (Figure 6.6), with an 
exception of their flexible loops present near the active site. CP fold is highly 
homologous among the CCP structures, with BcCCP overlaid with BmCCP (PDB code 
3k2k), SdCCP (PDB code 3l2n) and PaCCP (PDB code 4a39) giving r.m.s.d values of 
0.45 Å (374 Cα atoms), 0.85 Å (362 Cα atoms), and 1.07 Å (365 Cα atoms), 
respectively. This structural homology correlates well with the primary sequence 
identity of BcCCP and these proteins, which is about 85 %, 50 % and 40 %, 
respectively. 
 
Figure 6.6 Overlay of BcCCP with CP-A.  
Stereo image of an overlay of Cα traces from BcCCP (black) with bovine CP-A (red, PDB code 6cpa). 
The α6-α7 loop of BcCCP is drawn in cyan. The active site Zn2+ is shown as a grey sphere and a loop that 
remains disordered in BcCCP is marked with two asterisks. 
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BcCCP contains several motifs which are conserved among the CCP family members. 
One of them is an Asn-Pro-Asp-Gly sequence (Figure 6.5B), which likely helps with 
domain folding and contributes partially to the formation of the active site (Figure 6.7). 
In this motif, Asn216, located between α4 and β13, forms hydrogen bonds with the 
main chain Gln170 and a conserved Gly219. This in turn links the β12 and α4 together. 
In addition, Asp218 establishes hydrogen bonds to the side chain of Arg144 and the 
main chain of Glu142, both residues located on a loop between β10 and β11. This chain 
of hydrogen-bonding forms part of a larger network of interactions that hold β12 as well 
as β14 (not shown) in place, thereby contributing to formation of the active site because 
these β-strands provide His171 and His268, respectively to coordinate the catalytic 
Zn2+. 
 
Figure 6.7 The conserved Asn-Pro-Asp-Gly motif.  
On the left hand side, in stick representation, are shown the residues and selected hydrogen bonding 
interactions, as dashed black lines. The Asn-Pro-Asp-Gly residues are drawn in cyan. The right panel is a 
ribbon diagram of a subunit to indicate the position of this motif with respect to the overall fold. 
 
CCP proteins vary in length, with the mammalian proteins being considerably larger 
than their bacterial homologues due to the N- and C-terminal extensions plus numerous 
insertions. For example, CCP1 is the largest mammalian isoform with around 1200 
residues, of which 700 residues are the N-terminal extension. CCP6 is the shortest 
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mammalian isoform as it lacks the usually long N- and C-terminal extensions. Thus, the 
extra segments vary considerably in length, but their role is currently unknown. 
However, all CCP members contain three short sequence motifs within their N-terminal 
domain, which are absent in other carboxypeptidase families (Kalinina et al., 2007). 
The structure reveals that these conserved motifs are located in close proximity, even 
though they are distant in the primary amino acid sequence (Figure 6.5B; 6.8). Motif I 
F[D,E]xGx[L,I] (residues 9-14) is located at the N-terminus, followed by motif II 
W[F,Y][Y,N][F,Y] (residues 40-43) 60 residues downstream. This motif is located at 
the centre of the N-terminal domain. The conserved Trp40 and Phe41 form a 
hydrophobic core with other large hydrophobic residues such as Phe9, Phe57, Trp69, 
Trp83, Tyr110 and Phe111. Final motif III P[F,Y][S,T] (residues 113-115) is found at 
the N-terminus of α1 on the surface of the domain. This segment forms part of interface 
between the N-terminal and the CP domains. These motifs are also present in BmCCP, 
PaCCP and SdCCP structures (Figure 6.5B), and support the notion that the three 
conserved motifs are important for correct protein folding. However, a possibility that 
they might have additional roles cannot be eliminated.  
Figure 6.8 Three motifs common to 
the CCP family. 
These are: motif I (marine), motif II 
(orange), and motif III (purple). The 
active site Zn2+ is a grey sphere and the 
three-conserved motifs of the N-terminal 
domain found in all M14D family 
members are shown in marine and are 
labeled accordingly. 
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6.6.4 The active site and specificity 
In BcCCP, the active site is located in a groove, the floor of which is formed 
predominantly by residues in strands β14, β15 and β16. The walls of the groove are 
made out of four loops (α4-α5, α6-α7, β3-β4 and β5-β6) and the β14- β15 turn (Figure 
6.5). Here, the catalytic Zn2+ is penta-coordinated in a distorted tetrahedral geometry by 
His171, Glu174, His268 and a water molecule (Figure 6.9A). In addition, as mentioned 
earlier the active site also contains an acetate derived from the crystallisation conditions, 
which is held in place by Arg226, Arg236 and Asn235 (Figure 6.9A). 
 
Figure 6.9 The active site of BcCCP.  
(A) Zn2+ coordination in BcCCP. Selected residues in the active site and acetate are displayed and 
coloured as C white, or yellow for acetate, O red, N blue. The 2Fo-Fc electron density map is shown for 
acetate, where Fo are the observed and Fc are the calculated structure factors. The map is contoured at 1σ 
(cyan chicken wire). Zn2+ and a water ligand are shown as spheres, coloured grey and marine 
respectively. Zinc coordination is shown with black dashed lines and blue dashed lines represent 
hydrogen bonding interactions. (B) A comparison of BcCCP and bovine CP-A (PDB code 6cpa; Kim and 
Lipscomb, 1990) active sites. Residue side chains are depicted as sticks with atomic positions coloured O 
red, N blue and C cyan for bovine CP-A or all green for BcCCP. The Cα of Gly253 CP-A is a small black 
sphere. Zn2+ ions are overlapping grey spheres. 
 
The bacterial CCP active sites are structurally highly conserved and this conservation 
extends to cover many other carboxypeptidases. This is also true for the active sites of 
BcCCP and bovine CPA (Figure 6.9B), even though the two share only 21 % overall 
sequence identity. His171 and Glu174 residues are part of the His-Pro-Gly-Glu motif, 
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which is highly conserved in all CCP proteins (Figure 6.5B). In BcCCP and BmCCP, 
the nearby Arg169 helps to stabilise the spatial conformation of this motif by making a 
hydrogen bond to the main chain carbonyl of Pro172. Similar stabilising contacts are 
also observed in other available structures, but they involve different residues.  
In the case of bovine CPA, in addition to zinc coordinating ligands, other important 
residues involved in catalysis and possibly in substrate binding are Glu270 and Arg127. 
Arg127 helps to stabilize the oxyanion hole by binding to the carbonyl bond, while 
Glu270 acts as the general base for catalysis (Kim and Lipscomb, 1990). In the BcCCP 
structure, the residues in the equivalent positions are Glu344 and Arg226 (Figure 6.9B). 
Other residues conserved in the active site throughout the M14 family include Asn144 
and Arg145 of bovine CP-A, or equivalent Arg236 and Asn235 in BcCCP.  In the case 
of CP-A, these two residues interact with the C-terminal carboxylate group of the 
substrate. The Tyr248 in CPA structure, whose involvement in the catalytic process is 
still uncertain corresponds to Tyr315 in BcCCP (Rees et al., 1981; Gardell et al., 1985; 
Cho et al., 2001). It is worth noting that in addition to Tyr315, BcCCP contains another 
tyrosine residue Tyr320 near its active site. Both of these are located on an α6-α7 loop. 
Tyr320 is located on a more flexible part, which is found in two different orientations in 
BcCCP and BmCCP structures (Figure 6.10). The BcCCP structure displays an open 
configuration, whereas the BmCCP structure contains a closed configuration with 
Tyr320 directed into the active site. However, many loop residues including Tyr320 are 
not conserved among other CCP members.  
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Figure 6.10 The flexible segment of the α6-α7 
loop. 
The BcCCP and BmCCP (PDB code 3k2k) subunit 
structures are overlaid and the Cα trace for residues 
315 to 326 shown coloured green and blue/cyan 
respectively. The side chains of Lys319 and Tyr320 
are shown as sticks.   
   
 
 
 
 
In bovine CP-A and rat CP-A2, the substrate specificity is mostly determined by only a 
few residues placed in the vicinity of the S1’ site of the enzyme that binds the carboxyl 
terminus of the substrate (Faming et al., 1991). In the case of CP-A, these residues are 
Ile243, Asn144, Ala250, Gly253, Ile255, Asp256 and Thr268 (Garcia-Saez et al., 
1997). The residues Ile243, Ala250 and Tyr248 are found on a flexible loop, capping 
the S1’ site. Asn144 and Thr268 are both conserved in all CCP proteins and correspond 
to Asn235 and Thr342 in BcCCP. Ile255 in CP-A corresponds to Ser329 in BcCCP that 
is based at the bottom of the S1’ pocket. The nearby located Gly253 and Asp256 in CP-
A are replaced with Leu327 and Lys330 (Figure 6.9B), making the S1’ site in BcCCP 
shallower. The Lys330 is also present in BmCCP and might confer the specificity of the 
Burkholderia enzymes to act as the deglutamylases. Asn321 is identically placed in this 
position in SdCCP and PaCCP, thereby their S1’ subsites would still be able to 
accommodate the P1 glutamate on the substrate protein. 
In vitro assays were performed using a furylacryloyl glutamate derivative to test BcCCP 
for deglutamylase activity (data not shown). However, the hydrolysis reaction was 
inefficient, suggesting that either BcCCP might not possess deglutamylase activity, 
might require its specific substrate or might need activation similarly to bovine CP-A.  
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6.7 Conclusion 
The structure of a zinc-dependent BcCCP has been determined to 1.90 Å resolution. The 
crystals produced were small and when first analysed revealed a relatively long unit cell 
c dimension. For these reasons, the diffraction data were collected using a synchrotron 
microfocus beamline, which allowed the acquisition of a full data set. BcCCP contains 
relatively large asymmetric unit with four polypeptides, in total about 1500 residues. An 
unconventional strategy was chosen to speed up the refinement process, which utilised 
the automated protocols of PDB_REDO coupled with manual model-map inspections 
and rebuilding. This method led to an efficient refinement, highlighting the power of 
such protocols. The crystal structure revealed that both domains of BcCCP are 
structurally homologous to other solved structures of bacterial CCPs. The N-terminal 
domain of unknown function was to date only identified in CCP proteins, whereas the 
C-terminal domain is conserved in the M14 family. Eukaryotic CCPs were reported to 
be able to act as deglutamylases, and BcCCP might have the same function. The 
presence of Lys330 near the S1’ site provides further support to this. Nonetheless, 
deglutamylase activity was not observed against a furylacryloyl glutamate derivative. 
This indicates BcCCP might not be a deglutamylase; it might need activation or catalyse 
selective substrates, which to date were not identified. Therefore, further studies are 
required to answer these questions. 
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